Omadacycline (PTK 0796)  
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
Confidential and Proprietary  Page 1 of 79 Paratek Pharma, LLC  PROTOCOL PTK0796 -ABSI-[ZIP_CODE] 
Study Title  A Phase  3 Randomized, Double -Blind, Multi -Center Study to 
Compare the Safety and Efficacy of Oral Omadacycline to Oral 
Linezolid for Treating Adult Subjects with Acute Bacterial Skin and 
Skin Structure Infection (ABSSSI )  
IND Number:  73,431  and 75,928  
Protocol Number:  PTK0796 -ABSI -[ZIP_CODE]  
Indication:  Acute Bacterial Skin and Skin Structure Infection  
Phase:  [ADDRESS_635715] : Omadacycline ( PTK 0796 ) 
Dose Form : Oral  
Sponsor:  Paratek Pharma, LLC  
A wholly -owned subsidiary of Paratek Pharmaceuticals, Inc.  
[ADDRESS_635716] 
King of Prussia, PA, [ZIP_CODE] 
P.O. B
ox 120828 
[LOCATION_011], MA [ZIP_CODE] 
Tel:  +[PHONE_3119] 
Protocol Version:  Version 3.0 
Date:  22-NOV -2016 
[STUDY_ID_REMOVED]
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635717] With Linezolid  .....................34  13.1.1
13.2  Permitted Treatments  .............................................................................................35  
 Dressings  ......................................................................................................35  13.2.1
 Topi[INVESTIGATOR_494164] .........................................................................................35  13.2.2
 Surgical Procedures  .....................................................................................35  13.2.3
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635718] Demographics/Other Baseline Characteristics  ...............................37  14.2.1
[IP_ADDRESS]  Medical History Relating to the Infection Under Study  ....................[ADDRESS_635719] Reported Outcomes  .........................................................................38  14.2.5
[IP_ADDRESS]  Numerical Rating Scale for Pain  ........................................................38  
[IP_ADDRESS]  SF-36v2® Health Survey  ....................................................................[ADDRESS_635720] Article  .............................................................39  14.3.1
[IP_ADDRESS]  Treatment Phase  .................................................................................40  
[IP_ADDRESS]  Management While on Oral Test Article  ...........................................[ADDRESS_635721] Article:  Omadacycline  ................................................[ADDRESS_635722] Article:  Linezolid  ............................................................[ADDRESS_635723] Compliance ...............................................................................................44  
 SAFETY  ..........................................................................................................................45  16
16.1  Physical Examinations ...........................................................................................45  
 Vital Signs  ....................................................................................................45  16.1.1
 Laboratory Evaluations  ................................................................................46  16.1.2
[IP_ADDRESS]  Hematology ........................................................................................46  
[IP_ADDRESS]  Clinical Chemistry  .............................................................................47  
[IP_ADDRESS]  Other Laboratory Tests ......................................................................47  
 Safety Studies to be Performed Locally  .......................................................47  16.1.3
[IP_ADDRESS]  Electrocardiogram (ECG)  ..................................................................47  
[IP_ADDRESS]  Pregnancy and Assessments of Fertility  ............................................48  
[IP_ADDRESS]  Blood Cultures ...................................................................................48  
[IP_ADDRESS]  Additional Local Laboratory Tests ....................................................48  
 Appropriateness of Safety Measurements  ...................................................48  16.1.4
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635724] Demographics and Other Baseline Characteristics  ...................................60  
22.3  Treatments (Test Article, Rescue Medication, Other Concomitant Therapi[INVESTIGATOR_014], 
Compliance) ...........................................................................................................61  
22.4  Primary Efficacy Analysis  .....................................................................................61  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 5 of 79 Paratek Pharma, LLC   Early Clinical Response Efficacy Variable  ..................................................61  22.4.1
 Investigator’s Assessment of Clinical Response at PTE Efficacy Variable  61 22.4.2
 Statistical Model, Hy pothesis, and Method of Analysis ..............................61  22.4.3
 Additional Analyses of the Primary Efficacy Outcomes .............................62  22.4.4
22.5  Analysis of Secondary Variables  ...........................................................................63  
22.6  Analysis of Additional Efficacy Variables  ............................................................63  
22.7  Safety Outcome Measures .....................................................................................64  
 Adverse Events ............................................................................................64  22.7.1
 Vital Signs  ....................................................................................................64  22.7.2
 Electrocardiograms  ......................................................................................65  22.7.3
 Laboratory Tests  ..........................................................................................65  22.7.4
22.8  Resource Utilization  ...............................................................................................65  
22.9  Pharmacokinetics ...................................................................................................65  
 Population PK Modeling..............................................................................66  22.9.1
22.10  Pharmacogenetics/Pharmacogenomics  ..................................................................66  
22.11  Biomarkers  .............................................................................................................66  
22.12  PK/PD  ....................................................................................................................66  
22.13  Sample Siz e Calculation  ........................................................................................67  
22.14  Interim Analyses  ....................................................................................................67  
22.15  Handling of Missing Values/Censoring/Discontinuations .....................................[ADDRESS_635725] Article  .....................................................72  
27.2  Study Suspension or Termination ..........................................................................72  
 ETHICAL CONSIDERATIONS  .....................................................................................73  28
28.1  Regulatory and Ethical Compliance  ......................................................................73  
28.2  Informed Consent Procedures ................................................................................73  
28.3  Responsibilities of the Investigator and IRB/IEC/REB  .........................................73  
 PROTOCOL ADHERENCE  ...........................................................................................73  29
29.1  Protocol Amendments ............................................................................................74  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635726] INJURY  .........................................................................................................75  32
 PRESTUDY DOCUMENTATION  .................................................................................75  33
 RECORDS RETENTION ................................................................................................76  34
 PUBLICATION POLICY ...............................................................................................76  35
 REFERENCES (available upon request) .........................................................................[ADDRESS_635727] Article ..............................................................41  
Table  2. Oral Formulation  .....................................................................................................43  
Table  3. Hematology Panel ...................................................................................................46  
Table  4. Clinical Chemistry Panel .........................................................................................47  
Table  5. Additional Laboratory Tests  ...................................................................................47  
Table  6. Sample Size and Power Calculations ......................................................................67  
Table  7. Investigator’s Assessment of Clinical Response at PTE Determination Considering  
Missing Data ...........................................................................................................[ADDRESS_635728] OF APPENDICES  
Appendix 1.  Allowed and Disallowed Prior Antibiotics ........................................................78  
Appendix 2.  Equations and Conversion Factors .....................................................................79  
 
  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 7 of 79 Paratek Pharma, LLC   DISCLOSURE STATEMENT  1
Restricted Distribution of Documents 
This document contains information that is confidential and proprietary to the sponsor.  This 
information is being provided to you solely for the purpose of evaluating and/or conducting a clinical study for the sponsor.  You may disclose the contents of this document only to study 
personnel under your supervision, institutional review boards (IRBs)/independent ethics committees (I ECs) /research ethics boards (REBs) , or duly authorized representatives of 
regulatory agencies for this purpose under the condition that they maintain confidentiality.  The contents of this document may not be used in any other clinical study, disclosed to any other person or entity, and/or published without the prior written permission of the sponsor .  The 
foregoing shall not apply to disclosure required by [CONTACT_17140]; however, you will give prompt notice to the sponsor of any such disclosure.  All other nonpublic information provided 
by [CONTACT_494190]. 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 8 of 79 Paratek Pharma, LLC   CONTACTS  2
2.1 Emergency Contacts  
Name/Title :  Paul Eckburg, MD, Global Medical Monitor 
Phone (during business hours):  
Phone (after business hours):   
E-mail (not for emergencies):    
Address:        
          
 
 Name/Title: Stephen Villano, MD, Paratek Pharma , LLC, VP, Clinical and Medical Affairs  
Phone (during business hours):  
Phone (after business hours):   
E-mail (not for emergencies) :   
Address:         
          
 
  
 
2.2 Additional Contacts  
Serious Advers e Event (SAE) contact [CONTACT_3031]  
E-Mail:   
Fax:   

Omadacycline (PTK 0796) 
PTK0796-ABSI-[ADDRESS_635729] read and approve this protocol. My signature, in conjunction with the signature [CONTACT_94212], confirms the agreement of both parties that the clinical study will be conducted in 
accordance with the protocol and all applicable laws and regulations including, but not limited 
to, the International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (GCP), the Code of 
Federal Regulations (CFR), and the ethical principles that have their origins in the Declaration of 
Helsinki. 
~ Stephen Villano, MD 
VP, Clinical and Medical Affairs 
Paratek Pharma, LLC 
Confidential and Proprietary Date of Signature 
(DD-MMM-YYYY) 
Page 9 of79 Time 
(24-hour clock, time 
zone) 
Paratek Pharma. LLC 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635730] read the protocol (PTK0796- ABSI -[ZIP_CODE]) and agree to the following: 
The protocol contains all necessary details for carrying out this study;  
I will conduct the study as detailed in the protocol and will abide by [CONTACT_494191];  I will conduct the study in compliance with the most current versions of International Conference 
on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ( ICH) Guidelines for Good Clinical Practice  (GCP) , all applicable government regulations 
and the requirements of the IRB /IEC/REB that approved the study. 
I will train and supervise all individuals delegated to assist me in conducting this study, including providing copi[INVESTIGATOR_494165], the protocol and their responsibilities and obligations.  
I will use only the informed consent form (ICF) approved by [CONTACT_494192] (or their d esignee) and 
by [CONTACT_1201] /IEC/REB responsible for this study.  
I will fulfill all requirements for submitting pertinent information to the IRB/IEC/REB  and to 
PARATEK, including report able serious adverse events (SAEs) .  
I will provide PARATEK (or their desig nee) with access to any source documents from which 
case report form information may have been generated. I understand that the information in this protocol and the referenced Investigator’s Brochure  is 
confidential and that its disclosure to any third par ties (other than those involved in approving or 
conducting the study) is prohibited.  I will take the necessary precautions to protect this 
information from loss, inadvertent disclosure or access by [CONTACT_26404].  I will complete the study within the time  designated.  
My signature, in conjunction with the signature [CONTACT_8152], confirms the agreement of both parties that the clinical study will be conducted in accordance with the protocol and all applicable laws and regulations including, but not limited to, the I CH Guideline for GCP, the 
Code of Federal Regulations (CFR), and the ethical principles that have their origins in the Declaration of Helsinki.  
Nothing in this document is intended to limit the authority of a physician to provide emergency medic al care under applicable regulations.  
 
 
Investigator Signature   [CONTACT_1217]  
(DD-MMM- YYYY)   Time  (24-hour clock, 
time zone)  
     
Investigator Name [CONTACT_13693] (print)      
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635731]  aspartate aminotransferase  
AUC  area under the (concentration/time) curve  
BMI  body mass index  
BP blood pressure  
bpm beats per minute  
CABP  community -acquired bacterial pneumonia  
cc cubic centimeter  
CD4  cluster of differentiation 4  
CE clinically evaluable  
CFR  Code of Federal Regulations  
CK creatine phosphokinase  
CI confidence interval  
Cmax  maximum plasma concentration  
CrCL  creatinine clearance  
CRF  case report/record form  
CSA  clinical study agreement  
CSR  clinical study report  
cSSSI  complicated skin and skin structure infection  
EC European Commission  
ECG  electrocardiogram  
eCRF  electronic case report form  
EMEA  European Agency for the Evaluation of Medicinal Products  
EMA  European Medicines Agency  
EOT  end of treatment  
FDA  Food and Drug Administration  
g gravity  
GCP  Good Clinical Practice  
GI gastrointestinal  
β-hCG  beta-human chorionic gonadotropin  
HDPE  high-density polyethylene  
HIV Human Immunodeficiency Virus  
HPFB  Canadian Health Products and Food Branch  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635732]  
ITT intent -to-treat (population)  
IUD intrauterine device  
iv intravenous  
IxRS  Interactive Voice Response System/Interactive Web Response System  
LC/MS/MS  liquid chromatography/tandem mass spectrometry  
LDH  lactate dehydrogenase  
MAO  monoamine oxidase  
ME microbiologically evaluable  
MedDRA  Medical Dictionary for Regulatory Activities  
MIC  minimum inhibitory concentration  
Micro -mITT  microbiological modified intent -to-treat population  
mITT  modified intent -to-treat population  
MRSA  methicillin -resistant staphylococcus aureus  
NI non-inferiority  
PD pharmacodynamics  
PI [INVESTIGATOR_494166] (MedDRA)  
PTE post therapy evaluation (test of cure)  
PVC  polyvinyl chloride  
q12h  every 12 hours  
q24h  every 24 hours  
QTc corrected QT interval  
QTcB  QTc Bazett’s correction formula  
QTcF  QTc Fridericia’s correction formula  
REB  Research Ethics Board  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
SAS Statistical Analysis Software  
SBP systolic blood pressure  
SD standard deviation  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 13 of 79 Paratek Pharma, LLC  SOC  system organ class (MedDRA)  
spp species (pleural)  
ss steady state  
TEAE  treatment -emergent adverse event  
TFL table, figure  and listing  
TGA  Therapeutic Goods Administration  
Tmax  time to maximum plasma concentration  
ULN  upper limit of normal  
US [LOCATION_002]  
UTI urinary tract infection  
WBC  white blood cells  
 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 14 of 79 Paratek Pharma, LLC   DEFINITIONS  6
Term  Definition  
Regulation  The term regulation  refers to all applicable regulations, laws, and guidelines.  The 
regulations may be international, national, or local and may include but are not 
limited to the Code of Federal Regulations; the Good Clinical Practice:  Consolidated 
Guideline (Canada); the International Conference on Harmonisation Guideline for 
Good Clinical Practice; the Therapeutic Goods Administration Annotated International Conference on Harmonisation Guidelines (Australia); the World 
Medical Association Declaration of Helsinki :  Ethica l Principles for Medical 
Research Involving Human Subjects.  
Regulatory agency  The term regulatory agency  refers to all health and regulatory agencies with 
oversight responsibility for the study.  These may be international, national, or local 
and may include but are not limited to the Australian Therapeutic Goods Administration (TGA), the Canadian Health Pro ducts and Food Branch (HPFB), the 
European Agency for the Evaluation of Medicinal Products (EMEA), the  United 
States (US) Food and Drug Administration (FDA).  
Sponsor  The term sponsor  refers to, but is not limited to the Sponsor  listed in the front of this 
document and any contract research organization that is being used for the study.  
Test article  Any study drug, device, biologic agent, or comparator ( including placebo) used in 
sponsor  studies.  For test article accountability, this term applies to the above articles 
when they are required by [CONTACT_494193] (shipped) by [CONTACT_456] 
(including diluents such as sterile water for injection).  
Adverse event  An adverse event (AE) is any unto ward, undesired, or unplanned event in the form of 
signs, symptoms, disease, or laboratory or physiologic observations occurring in a 
person given a test article or in a clinical study.  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635733] s with Acute Bacterial Skin and Skin Structure Infection 
(ABSSSI ) 
Clinical Phase  [ADDRESS_635734] common 
ABSSSI pathogens, including methicillin- resistant Staphylococcus aureus  
(MRSA).  Omadacycline was evaluated in a Phase 2 study of 219 subjects 
with complicated skin and skin structure infection (cSSSI) and a sponsor- terminated Phase 3 study of 140 subjects with cSSSI.   
Omadacycline was well -tolerated and demonstrated efficacy similar to an 
established comparator (linezolid).  
In a global Phase 3 study comparing the safety and efficacy of intravenous (iv) and per oral (po) omadacycline to iv and po linezolid in the treatment 
of adult subjects with ABSSSI (PTK0796 -ABSI -1108) omadacycline was 
non-inferior to linezolid and was well tolerated .  In addition, a global 
Phase [ADDRESS_635735] s with community -acquired bacterial 
pneumonia (PTK0796- CABP -1200). 
This study is intended to evaluate the safety and efficacy of po 
omadacycline as compared to po linezolid in the treatment of adult subjects 
with ABSSSI.   
Study 
Objective(s) Primary objective:  
To demonstrate that omadacycli ne administered orally for [ADDRESS_635736] s with ABSSSI known or suspected to be due to 
Gram -positive pathogens.  
Secondary objectives:  
• To evaluate the safety of omadacycline in the treatment of adult 
subjects with ABSSSI.  
• To evaluate the Clinical Response according to th e identified 
causative pathogen. 
• To evaluate the pharmacokinetics (PK) of omadacycline in adult 
subjects with ABSSSI . 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 16 of 79 Paratek Pharma, LLC  Study Design This is a randomized (1:1), active comparator -controlled, double-blind, 
double-dummy, Phase [ADDRESS_635737] s with ABSSSI that is known or suspected to 
be due to a Gram-positive pathogen(s).  The Schedule of Events for the study is shown in Section  8.  Enrollment of subjects with major abscess 
may be up to 30% of randomized subjects.  Enrollment of subjects who 
have received a single dose of an allowed short -acting antibiotic (see  
Appendix 1
) within  the 72 hours prior to randomization will be limited to 
no more than 25% of randomized subjects .   
Approximate Duration of Subject Participation  Subjects will participate in the stud y for approximately [ADDRESS_635738] of the maximum length ( head -to-toe) multiplied by [CONTACT_494194] (measured 
perpendicular to length) as measured by [CONTACT_55296] a wound ruler.  Involved tissue is defined as tissue exhibiting clear evidence of one or more of the following:  erythema, edema or induration.  
The cl assification of qualifying infections is shown below. 
• Wound infection – an infection characterized by [CONTACT_494195] a wound with surrounding erythema, edema, and/or 
induration extending at least [ADDRESS_635739] distance from 
the peripheral margin of the wound.  
• Cellulitis /erysipelas – a diffuse skin infection characterized by 
[CONTACT_494196], edema, and/or induration.  
• Major abscess – an infection characterized by a collection of pus 
within the dermis or deep er with surrounding eryt hema, edema, 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 17 of 79 Paratek Pharma, LLC  and/or induration extending at least [ADDRESS_635740] distance 
from the peripheral margin of the abscess. 
4. Has evidence of a systemic inflammatory response within the 24 hours 
prior to randomization, as indicated by [CONTACT_494197]:   
• Elevated white blood cell (WBC) count (greater than or equal 
to 10,000 cells/mm3) or leukopenia ( less than or equal 
to 4,000 cells/mm3) 
• Elevated immature neutrophils ( greater than or equal to  15% band 
forms , see % bands calculation in Appendix 2) regardless of total 
peripheral white blood cell (WBC ) count 
• Lymphatic involvement :  lymphangitis or lymphadenopathy that is 
proximal to and in a location that suggests drainage from the 
qualifying infection 
• Fever or hypothermia documented by [CONTACT_093] 
(temperature  greater than  38.0°C [100.4°F] or less than  36.0°C 
[95.5°F]) 
5. Females must have a negative pregnancy test at Screening  and agree to 
comply with using a n accep table method of birth control (eg, 
abstinence, oral contraceptive,  intrauterine device [ IUD] , barrier 
contraception [condom] , tubal ligation, hysterectomy, bilateral 
oophorectomy, postmenopausal or vasectomized partn er) from 
Screening  through Post Therapy Evaluation ( PTE).  Males must agree 
to use an accep table method of birth control with female partner(s) and 
must not donate sperm from Screening  through PTE. 
Main Criteria for 
Exclusion 1. Has received 1 or more doses of a potentially effective systemic 
antibacterial treatment within the 7 2 hour period prior to randomization  
(a subject will be considered to have received a potentially effective 
systemic antibacterial treatment if the pathogen identified as causing the infection is shown to be susceptible to the antibacterial treatment given or, in the circumstance where a pathogen is not identified, if the antibacterial agent is approved for treatment of skin infections or is known to have activity against any of the leading Gram -positive causes 
of ABSSSI [eg, Staphylococcus aureus , Streptococcus  species [spp.], 
Enterococcus spp.). EXCEPTION: Subjects may be eligible despi[INVESTIGATOR_494167] a single dose of a short- acting , non-oxazolidinone antibacterial (ie, an antibacterial 
whose standard dosing regimen is more frequent than once per day, see list in  
Appendix 1).    
2. Has, for any reason, used a topi[INVESTIGATOR_494168](s) with specific 
antibacterial activity (eg, mupi[INVESTIGATOR_19190], retapamulin, fusidic acid) continuously within the 72 hour period prior to randomization, if applied to the skin for greater than or equal to 72 hours . 
3. Infections where the outcome is strongly influenced by [CONTACT_494198] -defined treatment and procedures, that require 
antib acterial  treatment for greater than 1 4 days, are associate d with 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635741] 
article,  eg: 
• chronic (persistently present  greater than  3 months) lesions, ulcers 
or wounds (eg, cellulitis contiguous with a diabetic foot ulcer)  
• association  with chronic dermatitis or any other chronic 
inflammatory skin lesion (eg, psoriasis, eczema)  
• burns 
• peri- rectal abscess (eg, buttock or peri neal lesion likely to 
communicate with the rectum) or perineal infection  
• infected decubitus (pressure) ulcers  
• necrotizing fasciitis (infections with rapi[INVESTIGATOR_494169])  
• life-threatening infections, ie, require emergency surgery for the 
treatment (eg,  progressive gangrene) 
• infections in an area requiring surgery that in and of itself would 
cure the infection or remove the infected site (eg, amputation for 
vascular insufficiency) 
• infections associated with severe vascular insufficiency (eg, 
peripheral vascular disease) or acute occlusion expected to require 
immediate revascularization  
• infections associated with acute compartment syndrome expected 
to require extensive surgery to provide decompression  
• infections acco mpanied by [CONTACT_494199] (eg, osteomyelitis, septic arthritis, bursitis)  
• bacteremic infections associated with an intravascular foreign 
body 
• infections accompanied by [CONTACT_494200] (eg, endocarditis, 
other endovascular infection, meningitis, visceral abscess, intra-abdominal infection, pneumonia, urinary tract infection) 
• human or animal bites  (infections associated with insect bites are 
NOT excluded) 
• myonecrosis 
• complicated by [CONTACT_115951] (eg, e cthyma 
gangrenosum in a neutropenic subject) 
• infections associated with the presence of a foreign body (eg, 
wood, metal, plastic, etc.) if the foreign body cannot be removed 
within [ADDRESS_635742] article  
4. Inability to tolerate oral medication (eg , nausea, vomiting, diarrhea or 
any other condition that might impair ingestion or absorption of oral medication).  
5. Has known or is clinically suspected for one or more of the following 
prior to randomization : 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 19 of 79 Paratek Pharma, LLC  • Alanine Aminotransferase ( ALT ) or Aspartate Aminotransferase 
(AST ) greater than or equal to  3 times the  Upper Limit of Normal 
(ULN),  
• total bilirubin greater than 1. [ADDRESS_635743], or 
• evidence of end- stage liver disease (eg, ascites, hepatic 
encephalopathy) 
6. Has a known history of having experienced unstable cardiac disease 
(eg, unst able angina, myocardial infarction, acute congestive heart 
failure, unstable cardiac arrhy thmia,  etc.) within the 3 months prior to 
Screening . 
7. Requires any form of dialysis (eg, hemodialysis , peritoneal dialysis ). 
8. History or evidence of severe renal disease or has a calculated 
creatinine clearance (CrCL) of less than  30 mL /min, using the 
Cockcroft- Gault equation  (see equation in Appendix 2). 
9. Evidence of significant immunological disease determined by [CONTACT_301568]: 
• Current or an ticipated neutropenia defined as less 
than 500 neutrophils/mm3 
• Known infection with Human Immunodeficiency Virus (HIV) and 
a cluster of differentiation 4 (CD4) count that is unknown or 
documented to be less than 200 cells/mm3 within the last year, or 
an Acquired Immune D eficiency Syndrome (AIDS)-defining 
illness  
10. The receipt of cancer chemotherapy, radiotherapy, or potent, 
non-corticosteroid immunosuppressant drugs (eg, cyclosporine, azathioprine, tacrolimus, immune -modulating monoclonal antibody 
therapy, etc.) within the 3 months  prior to Screening, or the receipt of 
systemic corticosteroids for more than 1 4 days in the 30 days prior to 
Screening . 
11. Requires acute pharmacologic intervention to stabilize blood pressure and/or adequate tissue perfusion , OR has evidence of septic shock, 
defined by [CONTACT_494201]:   
• Fever or hypothermia documented by [CONTACT_093] ( temperature 
greater than  38.0°C [100.4°F] or less than  36.0°C [95.5°F])  
• Heart rate greater than  90 beats/min (bpm) 
• Respi[INVESTIGATOR_172676] 2 0 breaths/min  
• WBC greater than 12,000 cells/mm
3 or less than  4,000 cells/mm3 
or greater than  10% immature (band) forms , see % bands 
calculation in  Appendix 2, re gardless of the total peripheral WBC 
count 
• Hypotension with systolic blood pressure (SBP) less than 90 mm  Hg d espi[INVESTIGATOR_494170] 20 to 30 cc/kg over 
a 30 min ute period  
• Perfusion abnormalities that may include, but are not limited to, 
lactic acidosis (blood lactate concentration  greater than or equal 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 20 of 79 Paratek Pharma, LLC  to 4 mmol/L), oliguria, or ac ute alteration in ment al status  
12. Pregnant or nursing (breastfeeding) women.  
13. Has a history of hypersensitivity or allergic reaction (eg, anaphylaxis, 
urticaria, other significant reaction) to any tetracycline (eg, minocycline, doxycycline or tige cycline) or to any oxazolidinone (eg, 
linezolid , tedizolid) . 
14. Has a history of pseudotu mor cerebri, or prior (within 2 weeks prior to 
Screening ) or planned concomitant use of isotretinoin. 
15. Has a history of systemic lupus erythematosus or lupus- like syndrome.  
16. Has current evidence of pancreatitis.  
17. Has received a monoamine oxidase inhibitor within 14 days prior to  
Screening  (eg, phenelzine, isocarboxazid, selegiline, moclobemide; 
which are typi[INVESTIGATOR_494171]'s Disease).  
18. Use of other investigational drugs within 5 half -lives or within  30 days 
prior to  Screening. 
19. Has previously been treated with omadacycline or previously enrolled 
in this study. 
20. Any planned medical intervention that might interfere with the ability to comply with the study requirements.  
21. Has any concomitant condition that, in the opi[INVESTIGATOR_871], is likely to interfere with evaluation of the response of the infection under study, determination of adverse events (AEs), or completion of 
the expected course of treatment.   
Prior and Concomitan t 
Treatment  No systemic prior or concomitant antibacterial therapy is allowed, other 
than a single dose of a short- acting antibacterial (see Exclusion Criterion 
number 1 and
 Appendix 1 ), within the [ADDRESS_635744] the 
known or potential infecting pathogen(s) responsible for the infection under study is allowed within the 7 2 hours prior to randomization or 
concomitantly through PTE.  No monoamine oxidase (MAO) inhibitors within [ADDRESS_635745]’s welfare may be administered and/or 
continued under the supervision of the investigator.  
Test Article(s)  Subject s will be randomized (1:1) to:  
• Omadacycline 
• Linezolid  
Dosage and Administration  • Omadacycline 450 mg  po every 24 hours (q24h) for 2 doses 
followed by 300 mg po q24h 
• Linezolid 60 0 mg po every 12 hours ( q12h )  
Safety Evaluation • Adverse events (AEs)  and Serious Adverse events (SAEs)   
• Physical exam ination s 
• Vital signs  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 21 of 79 Paratek Pharma, LLC  • 12-lead electrocardiograms (ECGs ) 
• Laboratory assessments 
• Pregnancy assessments  
Efficacy 
Evaluation • In order to satisfy different health authority requirements, the primary variables assessing efficacy will be teste d with 2 response 
endpoints: 
• Successful  Early Clinical Response ([ADDRESS_635746] article) defined as survival with a  greater than 
or equal to 20%  reduction of lesion size compared to 
Screening  measurements  without receiving any rescue 
antibacterial therapy  
• Successful  Investigator’s Assessment of Clinical Response at 
the Post Therapy Evaluation (PTE) visit defined as survival after completion of a test article regimen, with resolution or improvement of signs and symptoms of infection to the extent that further antibacterial therapy is not necessary  
• Lesion size  
• Microbiology of the infection  
Health Outcomes 
Assessment  • Resource utilization  
Pharmacokinetics  • Population pharmacokinetic (PK) analysis  
Statistical Analysis A number of subject analysis populations have been defined for the various 
analyses of efficacy and safety, as follows:  
• The intent- to-treat (ITT) population will consist of all randomized 
subjects 
• The modified intent- to-treat (mITT) population will consist of all 
randomized subjects without a so le Gram -negative cau sative 
pathogen(s) at Screening 
• The clinically evaluable (CE) population will consist of all mITT 
subjects who received test article, have a qualifying ABSSSI, an 
assessment of outcome,  and meet all other evaluability criteria 
detailed in the statistical analysis plan (SAP ) 
• The microbiological modified intent- to-treat (micro -mITT) 
population will consist of subject s in the mITT population who 
have at least 1 Gram -positive causative pathogen(s) at Screening  
• The microbiologically evaluable (ME) population will include 
subjects in the CE population who have at least 1 Gram -positive 
causative pathogen( s) at Screening  
• The Safety population will consist of all randomized subject s who 
receive test article  
A 2-sided 95% confidence interval (CI) approach for the difference in the 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 22 of 79 Paratek Pharma, LLC  rate of early clinical success in the mITT population ( primary analysis for 
the United State s [US] Food and Drug Administration [ FDA] ) will be used 
to test for non -inferiority (NI) of o madacycline arm compared to the 
linezolid arm.  For the primary analysis for the European Medicines 
Agency ( EMA ), 95% CIs for the difference in the rate of clinical success at 
PTE in the mITT and CE populations will be used to test for the NI of 
omadacycline arm compared to the linezolid arm.  
Safety will be assessed through the use of summary statistics and clinical review of reported AE s, changes in vital signs, ECGs and laboratory 
results obtained from blood and urine samples taken during the study.  
Rationale for Number of Subjects  The study is designed to show NI in the primary efficacy outcome of Early Clinical Response at [ADDRESS_635747] article 
in the mITT population.  An NI margin of 10% will be used for the analys is in the mITT population.  The NI margin was based on an analysis 
of the historical data regarding the treatment effect of antibiotics in ABSSSI.  
The sample size determination is based on ensuring sufficient power for the secondary efficacy analyses of Investigator’s Assessment of Clinical Response at PTE in the m ITT and CE populations (co- primary efficacy 
outcomes for EMA) as well as the primary efficacy analysis of Early Clinical Response.  For the Early Clinical Response primary efficacy endpoint, assuming an outcome rate of 79% for both treatment groups , NI 
margin of 10%, 90% power and a 1-sided alpha of 0.025, using the sample size determination method of Farring ton and Manning
12, a total of 
704 subjects are required . 
Assuming an 85% outcome rate in both treatment groups, NI margin of 10%, and a 1-sided alpha of 0.025, with a total of 704 subjects, there is more than 90% power to show NI for Investigator’ s Assessment of clinical 
response at PTE in the mITT population.  With an evaluability rate of 80%, there will be 564 subjects in the CE population.  Assuming a 90% outcome 
rate in both treatment groups, NI margin of 10% and a 1-sided alpha of 0.025, 564 subjects provides more than 90% power to show NI in the CE 
population.  
Ethical Considerations  This study will be conducted in accordance with applicable laws and regulations including, but not limited to, the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human use (ICH) Guideline for Good Clinical 
Practice (GCP) and the ethical principles that have their origins in the Declaration of Helsinki.  The institutional review board (IRB)/independent ethics committee (IEC)/research ethics board (REB)  must review and 
approve the protocol and informed consent form (ICF) before any subjects are enrolled.  The subject must be consented using the approved ICF 
before any procedures specified in the protocol are performed.  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 23 of 79 Paratek Pharma, LLC   STUDY FLOWCHART  8
Study Phase  Screeninga Double -Blind Treatment Phase  Follow -up Phase  
Study  Dayb  Day 1  Day 2  Day 3  
 (ECR [ADDRESS_635748] dose)  Day 7  Day 10c EOTd PTEe Final  
Follow -upf 
Day 30 -37 
Signed Informed Consentg X        
Demographics  X        
Medical /surgical  history  and current medical 
conditions  X        
Prior and concomitant  medication sh X X-------------------------- --------------- --------------------------------------------------------- -X 
Clinical assessment of the site of infectioni X  X X X X X X  
Assessment of lesion sizej X  X X X X X X  
Diagnosis of ABSSSI and photograph of the 
lesion sitek X        
Numerical Rating  Scale  for p ain at the primary 
lesion site  X  X   X X  
SF-36v2® Health Survey  X      X  
Physical examinationl X      X X  
Vital signs          
 Respi[INVESTIGATOR_697]  X X X X X X X X  
 Body temperature  X X X X X X X X  
 Blood pressure  X Xm Xn Xn X X X X  
 Pulse/heart rate  X Xm Xn Xn X X X X  
12-lead ECGo X     X    
Urine dipstick testp X        
Local u rine or serum pregnancy testq X        
Central s erum pregnancy testr X     X X  
Hematologys Xt  X X X X X  
Serum chemistrys Xt  X X X X X  
Blood cultureu X As Clinically Indicated  Xv Xv  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 24 of 79 Paratek Pharma, LLC  Study Phase  Screeninga Double -Blind Treatment Phase  Follow -up Phase  
Study  Dayb  Day 1  Day 2  Day 3  
 (ECR [ADDRESS_635749] dose)  Day 7  Day 10c EOTd PTEe Final  
Follow -upf 
Day 30 -37 
Culture of infection site & Gram stain  X As Clinically Indicated  Xv Xv  
Adverse Eventsw X X------------------------------------------------- ------------------------ ------------------------ X 
Review of Inclusion and Exclusion 
Criteria/Randomization (if Eligible)  X        
Test Article Administration and Accountabilityx  Xy Xz Xaa X X    
Plasma samples (in heparin) for PK analysesbb   X X      
Assessment of need to continue therapycc    X X    
Investigator’s Assessment of Clinical Response       X X  
ABSSSI  = Acute Bacterial Skin and Skin Structure infection; AE  = adverse event; β -hCG  = beta – human Chorionic Gonadotropin; ECG  = electrocardiogram; 
ECR = Early Clinical Response; eCRF  = electronic case report form; EOT  = end of treatment; ICF  = informed consent form; PK = pharmacokinetics; PTE  = post 
therapy evaluation; SAE  = serious adverse event.  
a Following the signing of an ICF, a ll Screening evaluations , with the exception of the blood culture sample collection,  should be completed within the 
[ADDRESS_635750]’s last day of study therapy.    
f To be conducted [ADDRESS_635751] been administered within the 7 days prior to the date of signing the ICF or during the Screening p hase will be recorded in the eCRF.  
All medications and significant non -drug therapi[INVESTIGATOR_014]  (including physical therapy and blood t ransfusions)  administered after the first dose of test article must be 
recorded in the eCRF.  
i Semi -quantitative description of infection features. Must be assessed within [ADDRESS_635752]’s lesion by [CONTACT_494202] × width .  The Screening measurement must be collected within [ADDRESS_635753] dose.  
k Diagnosis of the type of ABSSSI (wound infection, cellulitis/erysipelas or major abscess) and anatomical location.  A digital photograph of the infection site 
will be  taken at Screening only.  
l A full physical examination will  be completed at Screening; thereafter only changes from Screening  measurements should be recorded as AEs in the eCRFs.  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 25 of 79 Paratek Pharma, LLC  m Blood pressure and pulse rate should be measured within 30 min before, and approximately (± 15 minutes) [ADDRESS_635754] dose on Day 1. 
n Blood pressure and pulse rate should be measured within 30 min before, and approximately (± 15 minutes) [ADDRESS_635755] at the Central Laboratory at the Screening, EOT and PTE visits.   
s Blood will be collected for hematology (includes coagulation) and serum chemistry testing at the Central Laboratory at Screen ing and at the Day 3, Day 7,  
Day 10, EOT  and PTE  visits.  
t At the Screening visit, blood will be collected for local laboratory hematology and serum chemistry evaluations required for assessing subject eligib ility. 
u If bac teria are isolated from  blood cultures, repeat blood cultures should be collected . If subsequent blood cultures are also positive, repeat the blood cultures 
as necessary until negat ive blood cultures are obtained . 
v At the EOT and/or PTE visit, blood cultures and infection site specimen cultures and Gram stains should be obta ined only for subjects who are clinical 
failures and require alternative antibacterial treatment for the infection under study.  
w A subject’s AEs and SAEs will be recorded and reported from signing of the ICF to the Final Follow -up assessment.  
x A [ADDRESS_635756] will be provided by [CONTACT_1034].   
cc At the investigator’s discretion, all therapy may be discontinued after the 7th  day of treatment, when the infection is considered clinically cured (based on 
normalization of the clinical signs and symptoms of infection and the investigator’s clinical assessment that continued systemic antibacterial therapy is no 
longer needed).
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635757] – omadacycline (formerly named PTK 0796) – is the first member of 
the aminomethylcycline class of antibiotics, which are semi synthetic derivatives of the tetracycline class.  As a class, the tetracyclines have been in use for approximately [ADDRESS_635758] proven effective in the treatment of a variety of bacterial 
infections. Omadacycline is being developed for clinical use by [CONTACT_138838] (iv) and per oral  (po)  administratio n. The targeted indications enc ompass community -acquired bacterial 
pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infection (UTI).  
When first approved, the tetracyclines were an important component of the a ntibiotic 
armamentarium.  Their clinical use declined in subsequent years, due to the increasing 
prevalence of tetracycline resistance and the availability of effective alternative therapi[INVESTIGATOR_014].  
Over the past decade, Gram -positive bacteria with multi- drug re sistance to a diverse range of 
antibiotics have emerged as a major treatment challenge.  Two developments raise the specter that currently available antibiotics may become even less useful for treatment of infections caused by [CONTACT_6907] -positive organisms.  The  first is the emergence of vancomycin resistance in 
Enterococcus species ( spp.) and the subsequent transfer of those resistance elements to 
Staphylococcus aureus .  Although vancomycin- resistant Staphylococcus aureus  have not become 
epi[INVESTIGATOR_494172], their very existence raises concern because vancomycin has been 
the agent of choice for infections caused by [CONTACT_494203] -positive pathogens.  
The second important development is the appearance of community- acquired methicillin -
resistant Staphyloc occus aureus  (MRSA).
[ADDRESS_635759] been associated with numerous outbreaks of localized (skin and skin structure) and invasive (bacteremic) infections . 
Omadacycline is very active in vitro  against most Gram -positive pathogens.  It also exhibits 
activity against atypi[INVESTIGATOR_213574] (eg, Legionella spp.), and some anaerobic and Gram-negative pathogens.  The drug is active against strains expressing both mechanisms of tetracycline 
resistance as well as strains that are resistant to currently available antibiotics, including methicillin, vancomycin, e rythromycin, and ciprofloxacin.
[ADDRESS_635760] also been investigated.   In a Phase 2 study, 219 subjects 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 27 of 79 Paratek Pharma, LLC  with complicated skin and skin structure infections (cSSSI) were treated with omadacycline 
(n = 111) or linezolid (n  = 108); treatment was initiated with iv administration, with switch to po 
therapy at the discretion of the investigator.  In this study the total duration of study treatment was a mean of 1 0 and maximum of 20 days.  In a sponsor terminated Phase 3 study of similar 
design, 140 subjects with cSSSI were treated with  omadacycline (n  = 68) or linezolid (n  = 72) 
for a mean of [ADDRESS_635761] and reve rsible alanine aminotransferase (ALT) 
increases were seen , most notably with iv  doses of 300 mg or greater.  Transient increases in 
heart rate (HR) were observed following administration of single and multiple doses of 
omadacycline, with a dose depe ndent m ean increase of up to 1 5 to 20 beats per minute (bpm) 
compared to placebo.  The increases in HR were rarely reported as adverse events (AEs) and not 
associated with any other  cardiac findings.  These increases were most evident within the [ADDRESS_635762]- infusion.  Following po administration, an increased incidence of gastrointestinal (GI) AEs, 
particularly nausea, was noted in early studies, which were most not able at po doses of 400 mg 
or greater.  Of note, different po formulations evaluated in early studi es (eg, capsule v ersus 
tablet) may have influenced the GI safety profile.  In Phase [ADDRESS_635763] frequently reported AEs were GI related occurring in 19% of omadacycline treated and 17% of linezolid- treated subjects.  Nausea and vomiting were 
reported in 10% and 5%, respectively, of omadacycline- treated subjects primarily during po treatment, compared to 7 and 4%, respectively, of linezolid- treated subjects. Premature 
discontinuation of treatment due to an AE was very infrequent, occurring in 0.9% of omadacycline subjects and 1.9% of linezolid subjects.  There was no pattern of adverse changes in laboratory safety parameters among subjects treated with omadacycline or linezolid.  In 
particular, there was no clinical or statistical difference between the treatment groups in ALT values or in other liver enzymes.  
An increase in mean HR was observed, but to a les ser extent than what was observed in Phase 
[ADDRESS_635764] was transient and no QT prolongation was observed, consistent with the 
negative findings from testing of omadacycline in a dedicated corrected QT interval (QTc) study.  Three subjects treat ed with omadacycline had AEs of tachycardia; [ADDRESS_635765] article, and none resulted in discontinuation of study treatment. 
In the sponsor-terminated Phase 3 cSSSI study, 140 subjects were treated prior to the sponsor’s 
decision to discontinue the study (due to changing regulations regarding the endpoints).  The overall incidence of reported AEs in this study was comparable between the [ADDRESS_635766] commonly reported AEs (greater than or equal to 10% frequency in either treatment group) were nausea (27% omadacycline, 26% linezolid), he adache (24% omadacycline, 7% 
linezolid), vomiting (9% omadacycline, 15% lin ezolid), diarrhea (4% omadacycline, 18% 
linezolid), and dizziness (10% omadacycline, 8% linezolid).  Creatine phosphokinase (CK) elevation was reported in 9% of omadacycline treated subjects compared to 3% for linezolid.  Alanine Aminotransferase increases were reported as AEs in [ADDRESS_635767] (2%) 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 28 of 79 Paratek Pharma, LLC  compared to 4 linezolid treated subjects (6%).  Rash was reported by [ADDRESS_635768] 
(2%) and 6 linezolid subjects (8%).  Serious adverse events (SAEs) were experienced by 3 
omadacycline subjects (small bowel obstruction, large left pleural effusion, and worsening 
depression) and [ADDRESS_635769] (worsening right hand cellulitis). 
In a completed Phase 3 study comparing omadacycline and linezolid for the treatment of adults 
with ABSSSI (PTK0796 -ABSI-1108), subjects started therapy with omadacycline 100 mg iv  
every 12 hours (q12h) for  2 doses then 100 mg iv  every 24 hours (q24h), or linezolid 600 mg iv  
q12h.  Subjects could be switched to oral therapy (omadacycline 300 mg q24h or linezolid 600 mg q 12h) after a minimum of 3 days of iv therapy; the total treatment duration was 7 -14 days.  
Study results showed that omadacycline was non- inferior to linezolid.  In the modified intent- to-
treat population (mITT, total N=627) for omadacycline v ersus linezol id, respectively, clinical 
success based on a reduction of lesion size at [ADDRESS_635770] dose was 84.8% versus 
85.5% (95% confidence interval [CI]: -6.3, 4.9); clinical success based on investigator ’s 
assessment of clinical response at [ADDRESS_635771] dose was 86.1% versu s 83.6% (CI: -
3.2, 8.2).  Omadacycline was well tolerated: treatment- emergent adverse events (TEAEs) were 
reported in 48.3% versu s 45.7%; serious TEAEs in 3.4% versu s 2.5% and discontinuation due to 
TEAE in 1.9% versus 2.2% of omadacycline and linezolid treated subjects, respectively.  
In addition, a global Phase 3 study is currently being conducted to evaluate the safety and efficacy of iv and po omadacycline compared to iv and po moxifloxacin in the treatment of adul t 
subjects with community-acquired bacterial pneumonia (PTK0796- CABP -1200). 
Please refer to the current version of the omadacycline Investigator's Brochure for additional information .
[ADDRESS_635772] s with ABSSSI 
known or suspected to be due to Gram-positive pathogens.  
10.2 Secondary O bjectives  
• To evaluate the safety of omadacycline in the treatment of adult subjects with ABSSSI . 
• To evaluate the Clinical Response accordin g to the  identified causative pathogen. 
• To evaluate the pharmacokinetics (PK) of omadacycline in adult subjects with ABSSSI . 
 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 29 of 79 Paratek Pharma, LLC   STUDY DESIGN  11
11.1 Description  
This is a randomized (1:1), double-blind, double-dummy, active comparator -controlled, Phase [ADDRESS_635773] s with ABSSSI  
that is known or suspected to be due to a Gram-positive pathogen(s).  Enrollment of subjects 
with major abscess may be up to 30% of randomized subjects.  Enrollmen t of subjects who have 
received a single dose of an allowed short-acting antibiotic (see  Appendix 1) within  the 7 2 hours 
prior to randomization  will be limited to no more than 25% of randomized subjects.  Subject 
randomization will be stratified across treatment groups by [CONTACT_180890] (wound infection, cellulitis /erysipelas or major abscess) and  receipt of an allowed antibacterial therapy (see 
Appendix 1) in t he 72 hours prior to randomization, as defined in the Interactive Voice Response 
System/Interactive Web Response System  (IxRS ) specifications and statistical analysis plan 
(SAP) (see Section  25.1 ).   
The study will consist of 3 protocol-defined phases :  Screening, Double-Blind Treatment and 
Follow-up.  All Screening evaluations, with the exception of the blood culture, should be 
compl eted within the [ADDRESS_635774] article at the site within 4 hours after randomization. 
11.2 Rationale of Study Design  
The study was designed in accordance with  the [LOCATION_002] (US)  Food and Drug 
Administration  (FDA)3 and European Medicines Agency ( EMA )4,5 guidance on developi[INVESTIGATOR_494173], in addition to the guidelines of the Infectious Diseases Society of America (IDSA)
[ADDRESS_635775] article.   
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635776] (IRB) /independent ethics committee (IEC)/research ethics board (REB)  approved 
informed consent form (ICF) before any procedures specified in this protocol are performed . 
12.[ADDRESS_635777] ful fill ALL  of the following 
criteria:   
1. Written  and signed informed consent must be obtained before any assessment is performed.   
2. Male or Female, age [ADDRESS_635778] of the maximum length ( head -to-toe) multiplied by [CONTACT_494194] (measured 
perpendicular to length) as measured by [CONTACT_55296] a wound ruler.  Involved tissue is defined as tissue exhibiting clear evidence of one or more of the following:  erythema, edema or induration.  The classification of qualifying infections is shown below. 
• Wound infection – an infection characterized by [CONTACT_115950] a wound with 
surrounding erythema, edema, and/or induration extending at least [ADDRESS_635779] distance from the peripheral margin of the wound.  
• Cellulitis /erysipelas – a diffuse skin infection characterized by [CONTACT_153986], edema, and/or induration.  
• Major abscess – an infection characterized by a collection of pus within the dermis or 
deeper with surrounding erythema, edema, and/or induration extending at least [ADDRESS_635780] distance from the peripheral margin of the abscess.  
4. Has evidence of a systemic inflammatory response within the 24 hours  prior to 
randomization, as indicated by [CONTACT_209695]:   
• Elevated w hite blood cell (WBC) count (greater than or equal to  10,000 cells /mm
3) or 
leukopenia (less than or equal to 4,000 cells/mm3) 
• Elevated immature neutrophils ( greater than or equal to  15% band forms , see % bands 
calculation in  Appendix 2) regardless of total peripheral WBC count 
• Lymphatic involvement :  lymphangitis or lymphadenopathy that is proximal to and in 
a location that suggests drainag e from the qualifying infection 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 31 of 79 Paratek Pharma, LLC  • Fever  or hypothermia documented by [CONTACT_093] (tem perature greater 
than 38.0°C [100.4°F] or less than  36.0°C [95.5°F]) 
5. Females must have a negative pregnancy test at Screening  and agree to comply with using an 
accep table method of birth control (eg, abstinence, oral contraceptive, intrauterine device  
[IUD], barrier contraception [condom], tubal ligation, hysterectomy, bilateral oophorectomy, 
postmenopausal or vasectomized partner) from Screening  through Post Therapy Evaluation 
(PTE).  Males must agree to use an accep table method of birth control with femal e partner(s) 
and must not donate sperm from Screening  through PTE. 
 
12.[ADDRESS_635781] s fulfilling any of the following criteria are not eligible for inclusion in this study: 
1. Has received [ADDRESS_635782] erial treatment 
within the 7 2 hour period prior to randomization (a subject will be considered to have 
received a potentially effective systemic antibacterial treatment if the pathogen identified as 
causing the infection is shown to be susceptible to the antibacterial treatment given or, in the circumstance where a pathogen is not identified, if the antibacterial agent is approved for treatment of skin infections or is known to have activity against any of the leading Gram -positive causes of ABSSSI [eg, Staphylococcus aureus , Streptococcus species [spp.] , 
Enterococcus spp.]). EXCEPTION: Subjects may be eligible despi[INVESTIGATOR_494167] a single dose of a short-acting, non-oxazolidinone antibacterial (ie, an antibac terial whose standard dosing regimen is more frequent than once 
per day, see list in  Appendix 1).  
2. Has, for any reason, used a topi[INVESTIGATOR_494168](s) with specific antibacterial activity 
(eg, mupi[INVESTIGATOR_19190], retapamulin, fusidic acid) continuously within the [ADDRESS_635783] article,  eg: 
• Chronic (persistently present greater than  3 months) lesions, ulcers or wounds 
(eg, cellulitis  contiguous with a diabetic foot ulcer) 
• association with chronic dermatitis or any other chronic inflammatory skin lesion 
(eg, psoriasis, eczema)  
• burns 
• peri- rectal abscess (eg, buttock or perineal lesion likely to communicate with the 
rectum)  or perineal infection 
• infected decubitus (pressure) ulcers  
• necrotizing fasciitis (infections with rapi[INVESTIGATOR_494169])  
• life-threatening infections, ie, require emergency surgery for the treatment 
(eg, progressive gangrene) 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 32 of 79 Paratek Pharma, LLC  • infections in an area requiring surgery that in and of itself would cure the infection or 
remove the infected site (eg, amputation for vascular insufficiency) 
• infections associated with severe vascular insufficiency (eg, peripheral vascular 
disease) or acut e occlusion expected to require immediate revascularization  
• infections associated with acute compartment syndrome expected to require extensive 
surgery to provide decompression 
• infections accompanied by [CONTACT_494204] 
(eg, osteomyelitis, septic arthritis, bursitis)  
• bacteremic infections associated with an intravascular foreign body 
• infections accompanied by [CONTACT_494205] (eg, endocarditis, other endovascular infection, 
meningitis, visceral abscess, intra -abdominal infection, pneumonia, urinary tract 
infection)  
• human or animal bites  (infections associated with insect bites are NOT excluded)  
• myonecrosis 
• complicated by [CONTACT_494206] (eg, ecthyma gangrenosum in a 
neutropenic subject)  
• infections associated with the presence of a foreign body (eg, wood, metal, plastic, etc.) if the foreign body cannot be removed within [ADDRESS_635784] article  
4. Inability to tolerate ora l medication (eg, nausea, vomiting, diarrhea or any other condition 
that might impair ingestion or absorption of oral medication). 
5. Has known or is clinically suspected for 1 or more of the following prior to randomization : 
• Alanine Aminotransferase ( ALT ) or Aspartate aminotransferase ( AST ) greater than 
or equal to 3 times the Upper Limit of Normal (ULN),  
• total bilirubin greater than  1.[ADDRESS_635785], or  
• evidence of end- stage liver disease (eg, ascites, hepatic encephalopathy)  
6. Has a known history of having experienced unstable cardiac disease (eg, unst able angina, 
myocardial infarction, acute congestive heart failure, unst able cardiac arrhythmia, etc.) 
within the 3  months prior to Screening . 
7. Requires any form of dialysis (eg, hemodialysis , peritoneal dialysis ). 
8. History or evidence of severe renal disease or has a calculated creatinine clearance (CrCL) 
of less than 30 mL/min, using the Cockcroft-Gault equation (see  equation in Appendix 2).  
9. Evidence of significant immunological disease determined by [CONTACT_39132]: 
• Current or anticipated neutropenia defined as less than  500 neutrophils/mm
3 
• Known infection with Human Immunodeficiency Virus ( HIV) and a cluster of 
differentiation  4 (CD4 ) count that is unknown or documented to be less 
than 200 cells/mm3 within the last year, or an Acquired Immune Deficiency 
Syndrome ( AIDS )-defining illness 
10. The receipt of cancer chemotherapy, radiotherapy, or potent, non- corticosteroid 
immunosuppressant drugs (eg, cyclosporine, azathioprine, tacrolimus, immune-modulating monoclonal antibody therapy, etc.) within the 3 months prior to Screening , or the receipt of 
systemic corticosteroids for more th an 14 days in the 30 days prior to Screening . 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 33 of 79 Paratek Pharma, LLC  11. Requires acute pharmacologic intervention to stabilize blood pressure (BP) and/or adequate 
tissue perfusion, OR has evidence of septic shock, defined by [CONTACT_494201]:   
• Fever or hypothermia documented by [CONTACT_093] (temperature greater 
than 38.0°C [100.4°F] or less than  36.0°C [95.5°F])  
• Heart rate greater than  90 bpm  
• Respi[INVESTIGATOR_494174]  20 breaths/ min  
• WBC greater than  12,000 cells/mm3 or less than  4,000 cells/mm3 or greater  than 10% 
immature (band) forms , see % bands calculation in Appendix 2, regardless of the total 
peripheral WBC count  
• Hypotension with systolic blood pressure (SBP)  less than 90 mm Hg despi[INVESTIGATOR_494175] 20 to 30 cc/kg over a 30 min ute period  
• Perfusion abnormalities that may include, but are not limited to, lactic acidosis (blood 
lactate concentration greater than or equal to  4 mmol/L), oliguria, or ac ute alteration 
in mental status  
12. Pregnant or nursing (breastfeeding) women.  
13. Has a history of hypersensitivity or allergic reaction (eg, anaphylaxis, urticaria, other 
significant reaction) to any tetracycline (eg, minocycline, doxycycline or tigecycline ) or to 
any oxazolidinone (eg, linezolid , tedizolid). 
14. Has a history of pseudotumor cerebri, or prior (within 2 weeks prior to Screening ) or planned 
concomitant use of isotretinoin. 
15. Has a history of systemic lupus erythematosus or lupus- like syndrome.  
16. Has current evidence of pancreatitis.  
17. Has received a monoamine oxidase (MAO)  inhibitor within 1 4 days prior to  Screening  (eg, 
phenelzine, isocarboxazid, selegiline, moclobemide; which are typi[INVESTIGATOR_494171]'s Disease).  
18. Use of other investigational drugs within [ADDRESS_635786].  Limited information  including reason for screen failure  will 
be recorded on the electronic case report form (e CRF) or (IxRS) system  for screen failures. 
 PRIOR AND CONCOMITANT TREATMEN T [ADDRESS_635787] the 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635788] to notify the study site about any new medications he /she takes after the start of the test 
article .  All medications and significant  non-drug therapi[INVESTIGATOR_014] (including physical therapy and blood 
transfusions) administered after the subject starts treatment with test article  must be listed in the 
eCRF  (see Section 8 ).  In addition, for antibacterial agents, the dose, unit, frequency and route 
must  be entered in the eCRF.  
13.1 Prohibited  Treatment 
• Use of all non-study investigational medications or devices is prohibited during the 30 days 
prior to S creening through PTE.   
• Systemic antibacterial agents potentially effective for ABSSSI  are prohibited for 72 hours 
prior to randomization  through PTE, except as rescue therapy in cases of clinical failure.  A 
single dose of a short- acting potentially effective systemic antibacterial agent (see list in 
Appendix 1) administered within the 7 2 hours prior to randomization  will be allowed for up 
to 25% of randomized subjects.  
• Any topi[INVESTIGATOR_494176] a spectrum that is active 
against the known or potential infecting pathogen(s) responsible for the infection under study 
within the 72 hours prior to randomization through PTE. 
• MAO inhibitors.  Linezolid is a re versible non- selective inhibitor of MAO.  Therefore, 
subjects should not be enrolled who are either taking MAO inhibitors (eg, phenelzine, isocarboxazid), or have taken MAO inhibitors within 14 days prior to Screening.  MAO 
inhibitors are prohibited from 14 days prior to Screening through the Final Follow-up 
assessment . 
• Subjects will be instructed to avoid taking antacids and multivitamins containing multivalent 
cations (eg, aluminum, magnesium, calcium, bismuth, iron, or zinc) for [ADDRESS_635789]’s welfare may be administered and/or continued under the supervision of the investigator. 
 Concomitant Medications That May Intera ct With Linezolid  13.1.[ADDRESS_635790] be 
monitored closely for elevated blood pressure and other manifestations of serotonin syndrome which could include mental changes (eg, confusion, hyperactivity, memory problems), muscle twitching, excessive sweating, shivering or shaking, diarrhea, trouble with coordination, and/or fever.  
All subjects will be instructed to avoid eating foods high in tyramine content while taking test article as recommended in the linezolid prescribing information.  
The full prescribing information for linezolid will be provided to the i nvestigator under separate 
cover.  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 35 of 79 Paratek Pharma, LLC  13.2 Permitted  Treatments  
All other treatments not specified as prohibited are permitted during the study.  A single dose of 
a short- acting potentially effective systemic antibacterial agent (see list in  Appendix 1) 
administered within the 7 2 hours prior to randomization  will be allowed for up to 25% of 
randomized subjects.  Subjects requiring addi tional or alternative antibacterial therapy for the 
ABSSSI will be judged as Clinical F ailures and test article will be discontinued.  Further 
treatment for their infection is at the discretion of the investigator or the subject’s health care provider and will be considered as a concomitant medication.  
Subjects should be encouraged to contact [CONTACT_138844]. 
For all treatments received by [CONTACT_43966], relevant information must be 
recorded on the subject’s e CRF.  
 Dressings  13.2.1
Wounds may be covered with any sterile non-adherent type dressing (not containing any specific 
antibacterial agents) chosen by [CONTACT_941] i nvestigator.  
 Topi[INVESTIGATOR_2855] S olutions  13.2.2
Topi[INVESTIGATOR_494177].  However, solutions containing specific antibacterial 
agents (eg, mupi[INVESTIGATOR_19190], retapamulin, fusidic acid) should not be used as part of the regimen 
involved in local infection site care.  
 Surgic al Procedures  13.2.3Adjunct surgical treatment is appropriate and necessary in many ABSSSIs.  At Screening, all 
subjects should be carefully evaluated and a determination should be made as to whether [ADDRESS_635791] should be retained in the investigator ’s 
study files. 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 36 of 79 Paratek Pharma, LLC  14.1 Visit Schedule and Assessments  
Refer to  Section 8, for the study procedures and their time points. There are 3 protocol-defined 
phases of the study : Screening, Double-Blind Treatment, and Follow-up.  The study will have 
the following protocol-defined evaluations: 
• Day 1 visit  
• Day 2 visit 
• Day 3 visit ( Early Clinical Response [ECR] must be conducted between [ADDRESS_635792] article ) 
• Day 7 visit  
• Day 1 0 visit ( A Day 1 0 visit should be conducted f or subjects with treatment extending 
beyond 9 days, unless this vis it coincides with the End of Treatment visit) 
• End of Treatment (EOT) :  to be conducted on the calendar day of, or within [ADDRESS_635793] withdraws prematurely or terminates 
participation in the study before completion, the EOT visit should be conducted 
• Post Therapy Evaluation ( PTE) :  to be performed [ADDRESS_635794]’s last day of 
study therapy 
• Final Follow -up assessment :  Day 30 to 37 (after the first dose of test article ) 
 
Subjects who discontinue study treatment prematurely should have the EOT  visit and the 
procedures listed in Section 8, a PTE visit and a Final Follow -up assessment, if possible.  The 
site should also collect subject safety information through the Final Follow- up assessment.  
14.2 Screening Phase  
Due to the nature of the disease under study, the S creening  phase should be completed within 
1 day (24 hour period).  The Screening phase will be used to establish subject  eligibility and 
Baseline characteristics for each subject .  Subject s are eligible for Screening if they present with 
ABSSSI  signs and symptoms .  Following the signing of an ICF, site personnel will collect the 
following information: 
• Demographics 
• Medical/surgical history and current medical conditions  
• Physical examination 
• Vital signs  
• Review of inclusion/exclusion criteria 
• Laboratory tests:   hematology, chemistry, urine tests, pregnancy test (for women only) 
• 12-lead electrocardiogram (ECG) 
• Concomitant medications (past 7 days)  
• AEs since the signing of the ICF  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 37 of 79 Paratek Pharma, LLC  • Diagnos is of ABSSSI  (cellulitis /erysipelas, wound infection , or major abscess), clinical 
assessment  of the site of infection , and photograph of the infection site.  
• Assessment of lesion size 
• Numerical Rating Scale for pain at the primary infection site  
• SF-36v2® Health Survey 
• Microbiological assessments (blood culture, culture of the infection site, and Gram stains)  
 Subject Demographics/Other Baseline Characteristics  14.2.[ADDRESS_635795] demographic and Baseline characteristic data to be collected on all subjects include:  
date of birth, gender, race/ethnicity and childbearing potential.  M edical history/current medical 
condition data includes data until the signing of informed consent.  Whenever possible, diagnoses are to be recorded.  
The investigator will perform a comprehensive history and physical examination at the Screening  
evaluation with particular attention to items indicated below. 
[IP_ADDRESS] Medical History Relating to the Infection Under Study  
• Predisposing factors at the site of infection, eg, surgery, mechanical trauma, edema (acu te or 
chronic), vascular insufficiency, prior infection, iv  drug abuse 
• All systemic antimicrobials and topi[INVESTIGATOR_12969] (prescription, over- the-counter) from onset 
of the infection will be recorded under concomitant medications 
• Procedures (eg, debridement, incision and drainage) performed within the week (7 days) 
prior to Screening, including surgical (operating room, procedure room) procedures, 
interventional radiology procedures and bedside procedures, but excluding routine wound 
care such as dressing c hanges will be collected  
• Surgical procedure history for surgical wound infections (within 3 0 days prior to  Screening) 
 Physical Examination  14.2.2
At Screening, the physical examination will include the examination of general appearance, skin, 
neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities, vascular and neurological.  If indicated based on medical history and/or symptoms, rectal, external genitalia, breast, and pelvic exams may be performed.  Height and body weight will be measured.   
Information for all physical examinations must be included in the source documentation at the study site.  Significant findings that are present prior to the start of test article must be included in the subject’s eCRF.   
 Diagnosis o f ABSSSI and Clinical Assessment of the Site of Infection  14.2.3
At the Screening  evaluation , the type of ABSSSI will be recorded:  wound infection, 
cellulitis /erysipelas or major abscess as defined in the inclusion criteria (see Section  12.1).  To 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635796] be greater than or equal to  75 cm2 in total surface area of contiguous involved 
tissue ( ie, surrounding erythema, edema and/or induration).  
The anatomical location of the primary site of infection should be recorded.  F or subjects with 
multiple non- contiguous areas of infection, the i nvest igator will identify the most severely 
affected portion at S creening  and designate that as the primary lesion site .  The investigator 
should note the presence and nature of any foreign body (eg, wood, metal, plastic, etc.) present at 
the site of infection.   Note that if the foreign body cannot be removed within [ADDRESS_635797] should not be enrolled in the study (see Exclusion criteria, 
Section  12.2 ).  
The investigator will examine the primary site of infection and record the following information 
on source documents and the eCRFs: 
• Presence of l ymphadenopathy proximal to primary lesion site  
• Presence of l ymphangitis proximal to primary lesion site   
• Presence of drainage from the primary lesion site and description (serous/serosanguineous, 
seropurulent, or purulent) 
Semi -quantitative (none, mild, moderate, severe) description of infection for the following 
features : 
• Tenderness  
• Edem a 
• Erythema 
• Induration 
At the Screening evaluation  the site of infection will be photographed using a digital camera 
provided by [CONTACT_456] ; the subject number and date will be included in the field.  Instructions 
for lesion photographs will be provided to  the investigator.  
 Assessment of Lesion Size 14.2.[ADDRESS_635798] be collected within 4 hours prior to 
randomization.  Surface area of lesions will be calculated by [CONTACT_494207] -to-toe 
maximum length of the total  lesion and maximum width (perpendicular to maximum length) 
inclusive of contiguous involvement (erythema, edema and/or induration).  Investigator ruler 
measurements will be used to document the lesion size.  Instruction s for ruler measurements will 
be provided to the investigator .  
 Subjec t Reported Outcomes  14.2.5
[IP_ADDRESS] Numerical Rating Scale for Pain 
At the Screening, Day 3 (ECR), EOT and PTE visits the subject will complete a numerical rating 
scale for pain8 at the primary ABSSSI lesion site.  The numerical rating scale  anchors will range 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 39 of 79 Paratek Pharma, LLC  from 0 to 10, where 0 represents “No pain” and 10 represents “Pain as bad as you can imagine.” 
The subject will be asked to rate their pain at the primary site of infection under study: “ Please 
rate your pain by [CONTACT_494208] 24 hours, where 0 represents no pain and 10 represents pain as bad as you can imagine.”  
[IP_ADDRESS] SF-36v2
® Health Survey  
At the Screening and PTE visits the subject will complete  a SF -36v2® Health Survey  (Medical 
Outcomes Trust, OptumTM). The SF-36v2® Health Survey asks 36 questions to measure 
functional healt h and well -being from the subjec t's point of view. It is a practical, reliable and 
valid measure of physical and mental health that can be completed in five to ten minutes. It is 
referred to  as a generic health survey because it can be used across age (18 and older), disease, 
and treatme nt group, as opposed to a disease-specific health survey, which focuses on a 
particular condition or disease.  
 Urin e Test s 14.2.6
A urine dipstick  will be performed locally at  Screening.  Urine dipstick results will be recorded 
on the eCRF.  A local urine (or seru m) pregnancy test will be performed during S creening  for all 
women  and the results will be recorded on the eCRF . 
14.[ADDRESS_635799] article at the site within 4 hours after randomization. 
The following assessments (see Section 8) will be done: 
• Vital signs  
• AEs and SAEs  
• Concomitant treatments  
• Assessment of lesion size and clinical assessment of the site of infection   
• Numerical Rating Scale for pain at the primary infection site  
• Microbiological assessments  
• Blood for Central Laboratory assessments: hematology, chemistry , pregnancy (for women 
only) 
• Test article administration and accountability  
• Assessment for need to continue therapy 
• Investigator’s assessment of clinical response  
 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 40 of 79 Paratek Pharma, LLC  [IP_ADDRESS] Treatment Phase  
The study will employ a double-blind, double-dummy design using omadacycline placebo 
comparator tablets of matching size and shape to active omadacycline tablets and matching over- encapsulated placebo and over- encapsulated active linezolid tablets.  To maintain 
investigator and subject blinding, subjects on both arms will receive the same number of tablets as shown in Table [ADDRESS_635800] article should be taken with water.  There are fasting requirements for 
administration of the odd numbered doses due to effects of food on oral omadacycline (see  Table 
1).  These fasting requirements should be considered when determining the time of day when subjec ts will take their doses.  
In order to perform protocol-required procedures, Dose 1 and the odd numbered doses on Days 2 and 3 should be taken at the site.  Ability to perform the study procedures and the fasting requirements for the odd numbered doses should be considered when determining when subjects visit the clinic on Days 2 and 3.   
On Day 1, Dose 1 will be administered after the completion of all required Screening and Day 1 
procedures and within 4 hours after randomization as outlined in Section 8 .  On Day 1, a second 
dose should be taken  provided that 1) it can occur a minimum of 8 hours after Dose 1, and 2) it 
can occur a minimum of 8 hours before the expected time of the next dose (ie, Dose 3); otherwise only Dose [ADDRESS_635801] article will be taken  
twice daily, with approximately 12 hours (at least 8 hours) separating each dose.  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635802] Article  
Dosing   Omadacycline Arm  Linezolid Arm  Dosing Condition  
Day 1 Dose 1  Three 150  mg 
omadacycline tablets and 
one over-encapsulated 
placebo tablet resembling 
linezolid  Three placebo tablets 
resembling 
omadacycline and one over-encapsulated 
600 mg linezolid 
tablet   Fasting a  
Dose 2 b One over -encapsulated 
placebo tablet resembling 
linezolid  One over -encapsulated 
600 mg linezolid 
tablet   No restrictions  
Day 2 Dose 3  Three 150  mg 
omadacycline tablets and 
one over-encapsulated  
placebo tablet resembling 
linezolid  Three placebo tablets 
resembling 
omadacycline and 
one over-encapsulated 
600 mg linezolid 
tablet   Fasting a 
Dose 4  One over -encapsulated 
placebo tablet resembling 
linezolid  One over -encapsulated 
600 mg linezolid 
tablet  No restrictions  
Day 3 and all subsequent study days Dose 5 
and odd 
doses  Two 150  mg omadacycline 
tablets and one  over-
encapsulated placebo tablet 
resembling linezolid  Two placebo tablets 
resembling 
omadacycline and 
one over-encapsulated 
600 mg linezolid 
tablet   Fasting a 
Dose 6 
and even 
doses  One over -encapsulated 
placebo tablet resembling 
linezolid  One over -encapsulated 
600 mg linezolid 
tablet  No restrictions  
a  Fasting: no food, antacids or multivitamins containing multivalent cations (eg, aluminum, magnesium, calcium, 
bismuth, iron, or zinc) or drink except water for at least 6 hours before dosing; after dosing, no food for 2 hours, no 
dairy  products, antacids or multivitamins containing multivalent cations (eg, aluminum, magnesium, calcium, 
bismuth, iron, or zinc) for 4  hours  
b  On Day 1, Dose 2 should be taken  provided that 1) it can occur a minimum of 8 hours after Dose 1 and 2) it can 
occur a minimum of 8 hours before the expected time of the next dose (ie, Dose 3); otherwise Dose 2 should be 
skipped .   
[IP_ADDRESS] Management While on Oral Test Article  
While the subject is receiving therapy, the investigator should assess the subject at the visits 
specified in Section 8 and choose ONE  of the following actions: 
• Continue test article   
• Discontinue test article – this decision will prompt the EOT  evaluation  
The date, time and decision of the investigator will be recorded on source documents and the information transferred to eCRFs by [CONTACT_26271]. 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 42 of 79 Paratek Pharma, LLC  The investigator may use the culture and susceptibility results from the local microbiology 
laboratory to help guide therapy; however, decisions to continue or discontinue test article should 
be based on clinical response rather than susceptibility results (as omadacycline susceptibility testing is not available at the local site).  If the ABSSSI is caused by a microorganism that is not 
susceptible to linezolid in vitro , the decision to continue or discontinue study treatment should be 
based on the subject's clinical course and the investigator’s clinical judgment.  These cases 
should be discussed with the Medical Monitor.  The rationale for this decision should be recorded in source documents.  
 Permitted Dose Adjustments and Interruptions of Test Article  14.3.2
None. 
14.4 Follow -up Phase  
Subjects will be evaluated at 2 visits after the completion of treatment:  at the PTE visit, [ADDRESS_635803]’s last day of study therapy, and at a Final Follow- up assessment , [ADDRESS_635804] dose of treatment (see  Section  8).  The Final Follow- up assessment may be 
conducted via telephone contact [CONTACT_494209].  Otherwise, this assessment is to be performed with 
an in person study visit. 
14.[ADDRESS_635805] articles will be supplie d by [CONTACT_138841], LLC  (the sponsor).  Test article s will be labeled 
according to regulations. 
The test articles should be administered only to subjects who have provided informed consent 
and who meet all of the inclusion criteria and none of the exclusion criteria.  Once the test article has been assigned to a subject, it must not be reassigned to another subject.  
15.[ADDRESS_635806] Article Administration  
Subjects will be randomized (1:1) to 1 of the following 2 trea tment ar ms: 
• Investigational therapy:  omadacycline, 450 mg  po every 24 hours (q24h) for 2 doses, 
followed by 300 mg po q24h.  Tot al treatment duration of 7 to 14 days.  
• Reference therapy :  linezolid, 600 mg  po every 12 hours (q12h).  Tot al treatment duration of 
7 to 14 days.  
 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635807] Article:  Omadacycline  15.2.1
• 450 mg po q24h for 2 doses followed by 300 mg po q24h   
• Total treatment duration of  [ADDRESS_635808] Article:  Linezolid  15.2.2• 600 mg po q12h  
• Total treatment duration of  7 to 14 days 
15.3 Dose Selection Rationale  
The dosing regimen of omadacycline selected for this study is based on the totality of nonclinical 
and clinical experience to date, including in vitro  antibacteria l activity, PK characteristics, 
clinical efficacy in prior studies, and the overall safety and tolerability profile.   Key 
considerations in dose selection are summarized below:  
• Given the half-life of omadacycline (approximately 18 hours), if dosing were to occur 
once daily then several days of dosing would be required to reach steady- state plasma 
concentrations.  Consequently, dosing regimens typi[INVESTIGATOR_84688] a “loading- dose” 
strategy to reach steady -state more rapi[INVESTIGATOR_375].  

Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 44 of 79 Paratek Pharma, LLC  • In a completed Phase 3 study comparing omadacycline and linezolid for the treatment of 
adults with ABSSSI  (PTK0796- ABSI -1108) , subjects started therapy with omadacycline 
100 mg iv  q12h for 2 doses (ie, 2 doses on Day 1), then 100 mg iv q24h; after 3 days iv 
therapy subjects could be switched to oral therapy (300 mg po q24h) .  As described in 
Section 9.1, omadacycline demonstrated good efficacy and tolerability in that study.   
• It has been demonstrated that omadacycline administered as a 100 mg iv dose is 
bioequivalent (based on plasma area under the curve [AUC]) to a 300 mg oral dose.  
Therefore, one approach to the dosing regimen for this oral-only treatment study was to start omadacycline treatment with oral doses con sidered bioequivalent to the iv doses 
used in the completed Phase 3 study (ie, 300 mg po q12h for 2 doses, then 300 mg po q24h). 
• Because of a known food effect, oral omadacycline should be administered in a fasted 
state.  While this restriction is  considered manageable for once daily dosing, it was 
recognized that adherence to a fasting window surrounding two doses in a given day 
(such as that associated with a “loading -dose” of two separate doses on Day 1) would be 
challenging. 
• A recently completed Phase 1 study (PTK0796- MDPO-[ZIP_CODE]) evaluated multiple once 
daily oral regimens of omadacycline.  Preliminary results from that study showed that oral dosing regimens of [ADDRESS_635809] 2 days. 
• Therefore, in order to minimize the potential impact of food effects and maximize 
convenience with an oral dosing regimen that is expected to be well tolerated and achieve 
rapid target plasma concentrations, an omadacycline dosing regimen of entirely once daily dosing will be used (ie, 450 mg po q24h for 2 doses, then 300 mg po q24h).  Note 
that because the stud y is double -blind and linezolid is dosed twice- daily, all study 
subjects will be dosed twice- daily (with either active or placebo tablets), as detailed in 
Section [IP_ADDRESS]. 
15.[ADDRESS_635810] diaries. 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635811] article will be included in the evaluation for safety.  
Safety is assessed by [CONTACT_70731]:  
• Physical exam inations 
• AEs and SAEs  
• Vital signs  
• Laboratory a ssessments 
• 12-lead ECG  
• Pregnancy assessments  
 
16.1 Physical  Examination s 
After Screening, a  physical examination should be conducted on the study days indicated in 
Section  8. Any abnormalities or changes in intensity noted during the review of the body systems 
should be docume nted in the source documents.  If a new clinically significant finding occurs (ie, 
not noted at Scree ning) after the Screening exam, it must be captured as an AE.  In addition, 
resolution of any c linically significant abnormal findings that have been reported as an AE will 
be noted in the medical record and the AE eCRF. 
 Vital Signs 16.1.1
Vital sign s include BP, pulse/heart rate, body temperature, and respi[INVESTIGATOR_697] .  Vital signs 
should be recorded at all visits, with the exception of the Final Follow -up assessment  (see 
Section  8).  
• In addition, blood pressure and pulse rate should be measured within 30 min before, and 
approximately (± 15 minutes) [ADDRESS_635812] dose 
on Day 1 
• Blood pressure and pulse rate should be measured within 30 min before, and approximately (± 15 minutes) 1 hour after and 3 hours after the completion of the odd numbered dose on 
Day 2  
• Blood pressure and pulse rate should be measured w ithin 3 0 min before, and approximately 
(± 15 minutes) [ADDRESS_635813] dose measurements if possible, if not then a single 
measurement should be made at any time during the visit and the date and time recorded.  
 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635814]’s vital signs  should be captured after at least  [ADDRESS_635815] while in a 
non-standing position (supi[INVESTIGATOR_1662] -recumbent, head of bed from 0° to 90°).  Subsequent vital 
sign measurements should be captured in the same non-standing position. 
Systolic and diastolic blood pressure will be measured using an automated validated device, with 
an appropriately sized cuff.  
Pulse will be measured using an automated validated device, when available.  If not available, 
pulse will be measured manually.  
In addition to the above, BP and heart rate may be measured whenever clinically indicated at the 
discretion of the treating physician.  Any subject  who experiences an AE of cardiac chest pain, 
palpi[INVESTIGATOR_814], or tachy arrhythmia while on study should have an ECG and an evaluation by [CONTACT_1275] (see Section  [IP_ADDRESS]).   
Temperature will be obtained using an electronic (rapid reading) device whenever possible.  
Respi[INVESTIGATOR_494178]. 
 Laboratory Evaluations 16.1.2
Blood samples for hematology, serum chemistry and coagulation ( prothrombin time only ) should 
be drawn at the Screening , Day 3, Day 7, Day 10, EOT, and PTE visits (see Section  8).  At 
Screening  only, [ADDRESS_635816]’s 
meeting inclusion/exclusion criteria, it is expected that local laboratory testing will be used in 
circumstances where this testing is needed to assess a subject’s WBC count or differential, serum 
transaminase or bilirubin levels, serum creatinine or pregnancy testing  (for women only).  
[IP_ADDRESS] Hematology  
The analytes listed in  the table below (Table  3) will be measured  at the Central Laboratory . 
Table  3. Hematology Panel 
Hematocrit  
Total red blood cell count  
Hemoglobin  
Mean cell hemoglobin  
Mean cell hemoglobin concentration  
Mean cell volume  
White blood cell count  
Platelet count  White blood cell differential (as % cell counts)  
-Neutrophils  
-Lymphocytes  
-Monocytes  
-Eosinophils  
-Basophils  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 47 of 79 Paratek Pharma, LLC  [IP_ADDRESS] Clinical Chemistry  
The analytes indicated in  Table  [ADDRESS_635817]  
AP 
Total bilirubin  
Total protein  
Magnesium  
Albumin  
 LDH  
CK 
(CK isoenzyme testing as required)  
Calcium  
Phosphate  
Cholesterol  
Uric Acid  
GGT  
Amylase  
Lipase  
ALT  = Alanine aminotransferase ; AP = Alkaline phosphatase ; AST  = Aspartate aminotransferase ; 
CK = creatine phosphokinase ; GGT  = gamma -glutamyl transpeptidase ; LDH  = Lactate dehydrogenase.  
[IP_ADDRESS] Other L aboratory T ests 
Table  5. Additional Laboratory Tests 
Category  Test Note  
Coagulation  INR  Prothrombin time only  
Female endocrinology  β-hCG  (for 
women only)  See Section  [IP_ADDRESS]  below.  Done both locally (urine) and 
centrally (serum)  
β-hCG  = beta-human Chorionic Gonadotropin ; INR = international normalized ratio . 
 Safety Studies t o be Performed Locally  16.1.3
[IP_ADDRESS] Electrocardi ogram (ECG)  
A standard 12-lead ECG should be obtained using equipment provided by [CONTACT_456].  The ECG 
will be obtained after the subject has been in a semi -recumbent position for approximately 
10 minutes at the following times: 
• Screening  
• At the EOT visit  
• In any case in which a subject develops an AE of cardiac chest pain, palpi[INVESTIGATOR_814], tachyarrhythmia or as otherwise clinically indicated (see Section  16.1.1) 
Reading and i nterpretation  of the ECG will be performed centrally and provided to the 
investigator.  The investigator is responsible for reviewing interpretations and for retaining hard copi[INVESTIGATOR_191296].   
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 48 of 79 Paratek Pharma, LLC  [IP_ADDRESS] Pregnancy and Assessments o f Fertility  
All women will have a local urine or serum pregnancy test at the site at the Screening visit.  
Urine pregnancy test kits will be provided by [CONTACT_494210].  If a 
posit ive urine  or serum pregnancy test result is obtained at the site, the woman is not to be 
randomized.  A serum sample for β- hCG testing will be collected at the Screening visit and sent 
to the Central Laboratory for confirmation of the local urine or serum pregnancy test results.  
Serum samples for β-hCG testing at the Central Laboratory also will be collected at EOT and 
PTE.  If a positive β- hCG result is reported by [CONTACT_138851] a woman is enrolled, 
test article administration should be discontinued (see Section 21.2.6).  
[IP_ADDRESS] Blood C ultures  
Two sets of blood cultures (1 set  = 1 aerobic bottle + 1 anaerobic bottle) should be collected 
within the [ADDRESS_635818] 15 minutes apart.  Blood 
cultures should be collected for subjects that are clinical failures at the EOT and/or PTE visit.  If 
bacteria are isolated from blood cult ures, repeat blood cultures should be collected.  If 
subsequent blood cultures are also positive, repeat the blood cultures as necessary until negative blood cultures are obtained (see Section 8).  Blood culture isolates should be sent to the Central 
Laboratory (see Section  17.3).  
[IP_ADDRESS] Additional Local Laboratory Tests 
The investigator may order additional local labora tory tests consistent with his/her routine 
standard of care.  
 Appropriateness of Safety Measurements  16.1.[ADDRESS_635819] of key assessments that will be performed:  
• Clinical assessment of the site of infection  
• Assessment of lesion size 
• Assessment of the n eed for adjunct surgical procedures 
• Microbiological assessment of the infection  
• Assessment of clinical response by [CONTACT_093] 
• Assessment of all -cause mortality  
Each is described in further detail below. 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 49 of 79 Paratek Pharma, LLC  17.1 Clinical Assessment o f the Site of Infection  
The clinical assessment of the site of infection should be conducted at Screening and every 
scheduled evaluation with the exception of the Final Follow- up assessment (see Section 8).  A 
clinical  assessment of the site of infection must be performed within [ADDRESS_635820] the following 
information on source documents and the eCRFs : 
• Presence of drainage from the primary lesion site and description (serous/serosanguineous, 
seropurulent, or purulent) 
Semi -quantitative (none, mild, moderate, severe) description of infection for the following 
features : 
• Tenderness  
• Edema  
• Erythema 
• Induration 
17.2 Assessment of Lesion S ize  
Lesion measurements by [CONTACT_494211] , and every 
scheduled evaluation with the exception of the Final Follow- up assessment (see Section 8). 
Surface area of lesions will be calculated by [CONTACT_494207] -to-toe maximum length of total 
lesion and maximum width (perpendicular to maximum length) inclusive of contiguous 
involvement (erythema, edema and/or induration).  Investigator ruler measurement s will be used 
to document lesion size.  Instruction s for ruler measurements will be provided to the investigator. 
17.3 Microbiological Assessment o f the Site o f Infection  
At the  Screening  visit , material should be collected from the site of infection and submitted to 
site’s local microbiology laboratory for Gram stain and culture.  The type of specimen submitted 
will be recorded on source documents at the microbiology laboratory.  Laboratory repo rts on 
Gram stains should include a  semi -quantitative description of the number of polymorphonuclear 
leukocytes per low power field (ie, 100×) and a description of bacteria seen .  
It is critical, especially at  Screening , that the best possible specimen be obtained.  
As the site of infection responds to therapy, repeated cultures may not be clinically appropriate and/or there may be no material for culture.  At the EOT and/or PTE visit, infection site 
specimen cultures and Gram stains should be obtained only for subjects who are clinical failures and require alternative antibacterial treatment for the infection under study . 
The following types of specimens are considered accep table in or der of preference
6: 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 50 of 79 Paratek Pharma, LLC  • biopsy of involved cutaneous or subcutaneous tissue, preferably from the advancing margin 
of the lesion; 
• debrided tissue;  
• tissue scrapi[INVESTIGATOR_007] (using curette or scalpel);  
• needle aspi[INVESTIGATOR_494179], nonpurulent cutaneous or subcutaneous tissue;  
• pus or infected tissue collected during an incision and drainage procedure;  
• pus aspi[INVESTIGATOR_38105] a syringe;  
• deep swab of purulent material ( only if collected from infected tissue that has been incised or 
is draining).  
Surface swabs of wounds, inflamed skin, or drainage (including purulent material) are not 
accep table and should not be submitted.  For subjects with cellulitis /erysipelas, a 
skin/subcutaneous tissue punch biopsy at the ‘leading edge’ (not the center) of the involved area is preferred.  If this cannot be done, a needle aspi[INVESTIGATOR_494180] ‘leading edge’ of the cellulitic area 
should be performed. 
All specimens submitted to the site’s local laboratory are to be evaluated for aerobic and, where 
appropriate, anaerobic culture.  Culture results are to include a semi-quantitative description of the organisms on the primary culture plate and identification of all isolates to the level of genus 
and species.  Susceptibility testing for linezolid can be performed locally using a standard 
method chosen by [CONTACT_25699].  Results of this testing can be used by i nvestigators along with 
clinical findings to help guide therapy. 
All bacterial isolates identified by [CONTACT_494212] ( MIC ) testing performed for omadacycl ine, 
linezolid and a panel of currently approved antibiotics.  In the event that local laboratory genus and species identification are not consistent with Central Laboratory results, a back -up isolate 
should be sent to the Central Laboratory. 
The investiga tor is to check the laboratory microbiology specimen results.  If there is evidence of 
a Gram -negative or anaerobic microorganism, or microorganism that is non -susceptible to 
linezolid, the decision to continue or discontinue test article and change the antibacterial regimen 
is made based on the investigator’s clinical judgment and should be recorded in the source 
documents. 
Details concerning Gram stains and cultures will be provided in the Clinical Microbiology 
Laboratory Manual.  
17.4 Assessment of Clinical Ou tcome  
Assessment of clinical outcome will occur at the Early Clinical Response assessment  
(programmatically),  EOT, and PTE as described below.  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 51 of 79 Paratek Pharma, LLC   Evaluation of the Infection Under Study a t the Early Clinical Response 17.4.1
Assessment  
The formal determination of the response to therapy at the Early Clinical Response assessment 
([ADDRESS_635821] article) will be done programmatically using lesion 
measurement values entered into the eCRF .  The investigator is not responsible for categorizing 
subjects as Clinical Success, Failure, or Indeterminate at the Early Clinical Response assessment.   
Clinical Success at the Early Clinical Response assessment w ill be defined as meeting all 3  of the 
followin g: 
• The subject is alive  
• The size of the primary lesion has been reduced greater than or equal to  20% compared to 
Screening  measurements, without receiving any alternative ( rescue) antibacterial therapy.  
• The subject does not meet any criteria for Clinical F ailure or Indetermin ate (see below for 
definitions)  
Clinical Failure  will be defined as meeting any of the criteria below:  
• The size of the primary lesion has not been reduced by [CONTACT_55559]  20% 
compared to Screening  measurements  
• Investigator d iscontinued test article and indicated that the infection had responded 
inadequately such that alternative ( rescue) antibacterial therapy was needed  
• The s ubject received  antibacterial therapy that may be effective for the infection under study 
for a differ ent infection from the one under study 
• The s ubject developed an AE  that required discontinuation of test article prior to the Early 
Clinical Response assessment  and alternative (rescue) antibacterial therapy was needed  
• Death prior to Early Clinical Response assessment  
 
Indeterminate  
The clinical response to test article could not be adequately inferred because: 
• Subject was not seen for Early Clinical Response assessment because they withdrew consent, 
were lost to follow-up, other reason (specify) 
• Other, specify  
 Clinical Evaluation of the Infection Under Study a t EOT  17.4.2
At the EOT visit (on the day of or within [ADDRESS_635822] article) , the 
investigator will indicate the clinical status of the infection under study as detailed bel ow. 
Clinical Success at the End of Treatment assessment will be defined as meeting the following:  
• The subject is alive  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 52 of 79 Paratek Pharma, LLC  • The infection is sufficiently resolved such that further antibacterial therapy is not needed.  
These subjects may have some residual chan ges related to infection requiring ancillary (ie, 
non-antibiotic) treatment, eg, bandages on a healing wound, debridement of uni nfected tissue 
(ie, necrotic)  
Clinical Failure  will be defined as meeting any of the criteria below, the primary reason for 
clinical failure will be designated:  
• Investigator discontinued test article and indicated that the infection had responded inadequately such that alternative (rescue) antibacterial therapy was needed  
• The subject received  antibacterial therapy that may be effective for the infection under study 
for a different inf ection from the one under study 
• The subject developed an AE  that required discontinuation of test article prior to completion 
of the planned test article  regimen  and alternative (rescue) a ntibacterial therapy was needed  
• Unplanned major surgical intervention (ie, procedures that would not normally be performed at the bedside) for the infection under study 
• The subject died before evaluation  
• Other, specify 
Indeterminate  The clinical response to test article could not be adequately inferred.  The 
investigator will mark all that apply:  
• The subject was not seen for EOT assessment because they withdrew consent, were lost to follow-up, other reason (specify) 
• Other, specify 
 Clinical Evaluation of the Infection Under Study at PTE  17.4.[ADDRESS_635823] Therapy Evaluation PTE visit ([ADDRESS_635824]’s last day of study 
therapy) the investigator will indicate ONE  of the following outcomes relating to the primary 
infection under study :   
Clinical Success at the Post Therapy Evaluation assessment will be defined as meeting the 
following: 
• The subject is alive  
• The infection is sufficiently resolved such that further antibacterial therapy is not needed.  
These subjects may have some residual changes related to infection requiring ancillary (ie, 
non-antibiotic) treatment, eg, bandages on a healing wound, debridement of uni nfected tissue 
(ie, necrotic)  
Clinical Failure  will be defined as meeting any of the criteria below, the primary reason for 
clinical failure will be designated:  
• The infection required additional treatment with alternative (rescue) antibacterial therapy  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 53 of 79 Paratek Pharma, LLC  • The subject received antibacterial therapy between EOT and PTE that may be effective for 
the infection under study for a different infe ction from the one under study 
• Unplanned major surgical intervention (ie, procedures that would not normally be performed at the bedside) for the infection under study between EOT and PTE  
• The subject died before evaluation  
• Other, specify 
Indeterminate  The clinical response to test article could not be adequately inferred.  The 
investigator will mark all that apply:  
• The subject was not seen for PTE assessment because they withdrew consent, were lost to follow-up, other reason (specify) 
• Othe r, specify  
 OTHER ASSESSMENTS  18
18.1 Resource Utilization  
The number of emergency room visits and hospi[INVESTIGATOR_494181] . 
 PHARMACOKINETIC  PLASMA  SAMPLES  FOR OMADACYCLINE  19
CONCENTRATION  
19.1 Selection of Sites for PK Studies  
PK data will be analyzed using a population PK model.  In order to maximize the number of 
subjects who participate so that this analysis is optimal, during site selection the site’s ability to participate in the PK portion  of the study will be assessed .  Not all sites will participate in the PK 
portion of the study.  To assure the quality and accuracy of the PK samples, samples will be obtained only from subjects participating at a center that ha s the appropriate facilities and 
capabilities and has been specifically trained by [CONTACT_456].  
19.[ADDRESS_635825] between Days 2 and 3 (see Section  8). 
The sponsor will provide heparin tubes for the collection of PK blood samples and will provide 
freezer tubes for storing the plasma.  Blood will be collected either by [CONTACT_494213] a cannula used SOLELY  for that purpose. 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635826] 
minute should be immediately recorded on the tube.  The tube will be centrifuged at 150 0 × g for 
10 minutes; the separated plasma transferred in 2 equal aliquots into pre -labeled tubes; and the 
tubes frozen at -20ºC  or colder  within [ADDRESS_635827] s and be carefully packaged and shipped frozen at -20ºC or colder 
to the Central Lab oratory.  Samples are to  be shipped with sufficient dry ice to remain frozen 
during transit (up to a possibl e 4 day period) .  The Central Laboratory  will process these samples 
and forward them at -20ºC or colder to the Analytical Lab oratory  designated by [CONTACT_456].  For 
each subject  and time point, the  remaining  stored aliquots  will be retained on- site at -20ºC or 
colder until released or requested by [CONTACT_456]. 
19.4 Analysis of PK samples  
The Analytic al Lab oratory  will assay the samples for omadacycline using a specific, sensitive 
and validated Liquid Chromatography/Tandem Mass Spectrometry ( LC/MS/MS) method 
approved by [CONTACT_456]. 
 OTHER BIOMARKERS  [ADDRESS_635828] article or clinical study.  An AE 
includes, but is not limited to, the following: 
• Any clinically significant worsening of a preexisting condition. 
• An AE occurring from overdose of a test article, whether accidental or intentional.  
Overdose is a dos e greater than that specified in the protocol.  
• An AE occurring from abuse (eg, use for nonclin ical reasons) of a test article  
• An AE that has been associated with the discontinuati on of the use of a test article  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 55 of 79 Paratek Pharma, LLC   Serious Adverse Events 21.1.2
A SAE is an AE that:  
• Results in death  
• Is life -threatening (see below)  
• Requires hospi[INVESTIGATOR_138820] g hospi[INVESTIGATOR_059] (see below) 
• Results in a persistent or significant disab ility or incapacity (see below)  
• Results in a con genital anomaly or birth defect 
• Additionally, important medical events that may not result in death, be life -threatening, 
or require hospi[INVESTIGATOR_37347], based on appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent any one (1) of the outcomes listed  above in this definition.  
Examples of such events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in 
hospi[INVESTIGATOR_059], or development of drug dependency or drug abuse. 
Life-threatening refers to immediate risk of death as the event occurred per the reporter.  A 
life-threatening experience does not include an experience, had it occurred in a more severe 
form , might have caused death, but as it actually occurred, did not create an immediate risk of 
death.  For example, hepatitis that resolved without evidence of hepatic failure would not be 
considered life-threatening, even though hepatitis of a more severe na ture can be fatal.  
Similarly, an allergic reaction resulting in angioedema of the face would not be life -threatening, 
even though angioedema of the larynx, allergic bronchospasm, or anaphylaxis can be fatal. 
Hospi[INVESTIGATOR_138821] a hospi[INVESTIGATOR_307].  Hospi[INVESTIGATOR_17127] a 
hospi[INVESTIGATOR_138822]; however, it is not in itself considered 
an SAE.  In absence of an AE, a hospi[INVESTIGATOR_17127] a hospi[INVESTIGATOR_494182].  This is the case in the following 
situations:  
• The hospi[INVESTIGATOR_112041] a procedure required by [CONTACT_760] 
• The hospi[INVESTIGATOR_112042] a routine procedure 
followed by [CONTACT_16018] (eg, stent removal after surgery).  This should be recorded in the 
study file. 
• A hospi[INVESTIGATOR_272] a preexisting condition that has not worsened  
Disability is defined as a substantial disruption in a person’s ability to conduct normal life functions. 
If there is any doubt about whether the information constitutes an SAE, the information is treated 
as an SAE.  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635829] be recorded, reported, and followed 
up as indicated for an SAE.  This includes: 
• Pregnancy exposure to a test article :  If a pregnancy is confirmed, use of the test article 
must be discontinued immediately.  Information about pregnancy exposure includes the entire cou rse of pregnancy and delivery, and perinatal and neonatal outcomes, even if 
there are no abnormal findings.  Both maternal and paternal exposures are considered other repor table information.  For exposure involving the female partner of a male 
subject, the necessary information must be collected from the subject, while respecting 
the confidentiality of the partner.  
• Lactation exposure to a test article with or without an AE  
• Overdose of a test article as specified in this protocol with or without an AE  
• Inadvertent or accidental exposure to a tes t article with or without an AE  
 Overdose  21.1.[ADDRESS_635830]’s treatment 
assignment by [CONTACT_123517].  IxRS will also provide a confirmation report of the drug assignment to site personnel.  The site personnel will retain this confirmation report.  
The physician managing the overdose may order any test he/she thinks is necessary to manage the subject properly. 
 Medication Errors 21.1.[ADDRESS_635831], at the wrong time, and/or by [CONTACT_138855], due to human error.   
Medication errors include, but are not limited to, the followin g: 
• The administration and/or consumption of test article that has n ot been assigned to the 
subject 
• Administration of expi[INVESTIGATOR_494183] a medication er ror.  A medication error associated with an SAE (including 
overdose, inadvertent exposure, and/or accidental exposure) will be reported with the SAE on the SAE Report  Form.  All other medication errors will be reported by [CONTACT_494214] e- mailing the 
Clinical Test Article Error Incident Report Form as indicated in the Emergency Contacts (see 
Section  2). 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635832]’s AEs and SAEs will b e recorded and reported from the signing of the ICF to the time 
of the Final Follow- up assessment.  The investigator must instruct the subject to report AEs and 
SAEs during this time period.  Reports of death within [ADDRESS_635833] should be asked the following nonspecific question :  "How have you been feeling since 
your last visit?"  Whenever possible, AEs should be reported as a diagnosis rather than 
individual signs and symptoms.  If a definitive diagnosis is not possible, the individual signs and symptoms should be recorded using standard medical terminology. 
If an AE requires a surgical or diagnostic procedure, the illness leading to the procedure should 
be recorded as the AE, not the procedure itself.  
Death should be recorded in the eCRF as an outcome of an AE.  Any unanticipated risks to the subjects must be reported promptly to the IRB/IEC/REB.   
 Serious Adverse Event Reporting  21.2.[ADDRESS_635834] be reported within 1 business day or 24 hours as 
required by [CONTACT_494215] a completed SAE Report Form to the fax number below or e-mailing a completed SAE Report Form to the email address below.  
Serious Adverse Event (SAE) contact [CONTACT_3031]: 
E-Mail:   
Fax:   
 Assessment of Relatedness 21.2.2
The investigator will assess causality (ie, whether there is a reasonable possibility that test article 
caused the event) for all AEs and SAEs.  The relationship will be characterized using the 
following classification:  
• Not related: This relationship sugge sts that there is no association between test article and the 
reported event.  The event can be explained by [CONTACT_494216] (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635835] article  and the event. 
• Related: This relationship suggests that a definite causal relationship exists between test 
article  administration and the AE, or there is a reasonable possibility that the event was 
caused by [CONTACT_7860], and other conditions (concurrent illness, 
progression/expression of disease state, or concurrent medication reaction) do not appear to 
explain the event.  
AEs and SAEs  also will be assessed for their potential relationship to the protocol.  A protocol-
related adverse event is one that is not related to the test article, but is considered by [CONTACT_221739] (or designee) to be related to the research conditions, ie, related to the fact that a subject is participating in the study.  For example, a protocol- related AE 
may be an untoward event related to a medical procedure required by [CONTACT_760]. 
 Assessment of Severity  21.2.3
The severity (or intensity) of an AE will be classified using the following criteria:  
• Mild: These events are usually transient, require minimal or no treatment, and do not 
interfere with the subject’s daily activities.  
• Moderate: These events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with n ormal functioning but pose 
no significant or permanent risk of harm. 
• Severe: These events interrupt a subject’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually incapacitating.  
Changes in the severity  of an AE should be documented as a new event to allow an assessment 
of the duration of the event at each leve l of intensity to be performed.  
 Laboratory Findings 21.2.[ADDRESS_635836]’s baseline assessments and clinical course, and not known to be part of another AE diagnosis. 
 Worsening or Progression of Qualifying ABSSSI 21.2.[ADDRESS_635837] for entry in the study (“qualifying ABSSSI ”) is 
unique because data regarding the progress of this infection are being capture d as part of efficacy 
analyses.  Therefore, worsening or progression of the qualifying ABSSSI should be recorded as a 
clinic al failure (as part of the efficacy assessment), rather than an AE, unless the 
worsening/progression also meets the criteria for a serious AE (in which case the event also should be reported as an SAE).   In contrast, any new  or secondary  infections that th e investigator 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635838] from the qualifying ABSSSI (eg, a secondary skin abscesses in a 
different anatomical location) should be reported as AEs in all cases, whether non -serious or 
serious.  
 Pregnancies  21.2.[ADDRESS_635839] article should be discontinued 
immediately and the pregnancy should be followed up to determine outcome, including 
spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. 
Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported by [CONTACT_27719].  Pregnancy follow-up should be recorded on the same form and 
should include an assessment of the possible relationship to the test article of any pregnancy outcome.  Any SAE experienced during pregnancy must be reported on the SAE Report Form. 
 DATA ANALYSIS  22
All analyses of data for this study will comply with International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH -E9) and the 
sponsor’s guidance documents and standards.  Statistical analyses will be performed using Statistical Analysis Software (SAS). 
A SAP incorporating the sections below and with mock table, figure and listing (TFL) shells will 
be prepared prior to the start of the study and approved and finalized by [CONTACT_414376].  This plan will define populations for analysis, outline all data handling conventions and specify statistical methods to be used for analysis of safety  and efficacy.  As a 
consequence of differing regulatory requirements for the choice of the primary efficacy outcome and statistical analyses, 2 separate SAPs will be prepared (FDA and EMA).  The sections below 
indicate the overall structure and approach of the analyses.  
Inferential statistic al analyses of the primary and secondary outcomes will be conducted as 
outlined below.  Descriptive statistics, including the numbers and percentages for categorical variables, and the numbers, means, standard deviations (SD) , medians, minimums, and 
maximums for continuous variables will be provided.  All comparisons will be for omadacycline versus linezolid.  Exploratory analyses may also be performed.  Listings of individual subject ’s 
data will be produced.   
22.[ADDRESS_635840] been defined for the various analyses of efficacy and safety, as follows: 
• The intent- to-treat (ITT) population will consist of all randomized subject s. 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 60 of 79 Paratek Pharma, LLC  • The modified intent- to-treat (mITT) population will consist of all randomized subjects 
without a sole Gram -negative causative pathogen(s)  at Screening .   
• The clinical ly evaluable (CE) population will consist of all mITT subject s who received test 
article, have a qualifying ABSSSI , an assessment of outcome, and meet all other evaluability 
criteria  detailed in the SAP.   
• The microbiological modified intent- to-treat (micro -mITT) population will consist of 
subject s in the mITT population who have a t least 1 Gram -positive causative pathogen (s) at 
Screening . 
• The m icrobiologically evaluable (ME) population will include subjects in the CE population 
who have a t least 1 Gram -positive causative pathogen(s) at Screening .  
• The safety population will consist of all randomized subjects who receive test article.  
22.[ADDRESS_635841] Demographics a nd Other Baseline Characteristics  
Descriptive statistics, by [CONTACT_2939] , will be provided for the following: 
• Subject disposition:  
• completed test article  
• discontinued test article by [CONTACT_41794] 
• completed study 
• discontinued study by [CONTACT_41794] 
• Protocol deviations 
• ABSSSI background information 
• Subject demographics :  age (years), gender, race/ethnicity , height (cm), weight (kg), 
Body Mass Index (BMI ) (kg/m2) 
• Description and location of the primary site of the ABSSSI  
• type of infection 
• site of infection  
• area (length × width) of the lesion  
• presence of systemic signs of infection  
• severity of clinical signs and symptoms 
• culture source and type of specimen by [CONTACT_494217]  
• Surgical procedures 
• Medical histories and continuing medical conditions 
Screening  demographic and medical vari ables will be analyzed using a 2-sided Fisher’s exact 
test (for categorical variable s) or a 2-sided Wilcoxon Rank Sum test  (for ordinal and continuous 
variables).  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 61 of 79 Paratek Pharma, LLC  22.3 Treatments (Test Article, Rescue Medication, Other Concomitant Therapi[INVESTIGATOR_014], 
Compliance)  
A listing will be provided that indicates the subject’s date and time of randomization, 
randomized treatme nt assignment, randomized infection type and receipt of allowed antibacterial 
therapy in the [ADDRESS_635842] was 
randomized.  For the primary analyses for both the FDA and EMA, subjects will be analyzed in the stratum to which they were randomized (see Section  25.1 ). 
 Early Clinical Response Efficacy Variable  22.4.1
The Early Clinical Response can be Clinical Success, Clinical Failure and Indeterminate (defined 
in Section  17.4.1).  
An Indeterminate Response is included in the denominator for the calculation of the percentage 
of subjects with a Clinical Success in the m ITT population and thus, is essentially considered as 
a Clinical Failure for the purpose of the primary analysis for the FDA .  
 Investigator’ s Assessment of Clinical Respons e at PTE Efficacy Variable  22.4.2This is defined as Investigator ’s Assessment of Clinical Response at the PTE visit with outcomes 
of Clinical S uccess, Clinical Failure and Indeterminate (defined in Section  17.4.3) in the mITT 
population and Clinical Success and Clinical Failure in the CE population.  Subjects with a 
response of Clinical Failure at EOT will be defined as a Clinical Failure at PTE.  An 
Indeterminate Response is included in the denominator for the calculation of the percentage of 
subjects wi th a Clinical Success in the mITT population and thus, is  essentially considered a 
Clinical Failure for the purpose of the primary analysis for the EMA.  
 Statistical Model, Hypothesis, and Method o f Analysis  22.4.3
To demonstrate the efficacy of omadacycline is non -inferior to linezolid  in the treatment of adult 
subjects with ABSSSI, the following hypothesis will be evaluated by [CONTACT_494218] C linical 
Success rates . 
The null hypothesis and alternate hypothesis for the  Early Clinical Response endpoint will be  
assessed in the mITT population  as follows:  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 62 of 79 Paratek Pharma, LLC  Ho:  θT – θC ≤ -∆ 
Hai:  θT – θC > -∆  
Where the clinical success rate for the omadacycline regimen is θ T and for linezolid is θ C  
∆ is the non- inferiority ( NI) margin and is 0.10.   
Similar null and alternative hypotheses can be set up with ∆ of 0.10 for the PTE endpoint.  For 
the Early Clinical Response (FDA) endpoint, a 2-sided 95% confidence interval (CI) approach 
for the difference of clinical success rates (using the point estimate of the difference:  
omadacycline  response proportion minus linezolid response proportion) will be used to test for 
the NI of the omadacycline arm compared to the linezo lid arm in the mITT population.  The 95% 
CI will be calculated using the unstratified method proposed by [CONTACT_240865].9  
Omadacycline will be considered non- inferior to linezolid if the lower bound of the CI is greater  
than -0.10. 
For Investigator’s Assessment of Clinical Response at PTE (EMA) primary efficacy analyses in 
both the mITT and CE populations , a 2-sided 95% CI approach for the difference of clinical 
success rates (using the point estimate of the difference :  omadacycline response proportion 
minus linezolid  response proportion) will be used to test for the NI of the omadacycline arm 
compared to the linezolid  arm.  The 9 5% CI will be calculated using the stratified (for the 
randomization stratification factors) method proposed by [CONTACT_240865].9  
Omadacycline will be considered non- inferior to lin ezolid if the lower bound of the CI is greater  
than -0.10. Early Clinical Response and Investigator’s Assessment of Clinical Response at PTE will be 
tested separately and are not co -primary endpoints.  The probability for approving an ineffective 
drug based on PTE efficacy is  2.5%, regardless of the result for the Early Clinical Response 
endpoint and vice versa.  An adjustment would only be required if winning on at least 1 endpoint 
would result in global approval which is not the case here.  In addition, no alpha adjustment is needed for the co-primary efficacy endpoints for the EMA (mITT and CE populations) since NI must be shown in both populations to  conclude NI.  Hence there will be no adjustment for 
multiple endpoints.  
 Additional Analyses of the Primary Efficacy Outcomes  22.4.4
Additional and sensitivity analyses of the primary efficacy outcomes (Early Clinical Response 
and Investi gator’s Assessment of Clinical Response at PTE) will be performed.  Analyses for the 
FDA primary efficacy outcome will be described here and in more detail in the SAP.  Analyses 
for the EMA primary efficacy outcome will be described in the SAP. 
If the null hypothesis of inferiority is rejected for the Early Clinical Response in the mITT population and the observed success response proportion for omadacycline is larger than the observed proportion for linezolid, a formal statistical analysis of superiority w ill be conducted.  
If the lower limit of the 2-sided 95% CI for the treatment difference is greater than 0%, 
omadacycline will be considered superior to linezolid . 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 63 of 79 Paratek Pharma, LLC  The primary efficacy outcome will be assessed separately across the stratification factors of type 
of infection and receipt of allowed antibacterial therapy in the 7 2 hours prior to randomization  
stratum by [CONTACT_1570].  For each type of infection stratum and each prior antibacterial 
therapy stratum, a 2 -sided 95% CI for the observed differe nce in Early Clinical Response rates 
will be calculated for the mITT population.  Additional subgroup analyses of the primary 
efficacy outcome may be conducted as descriptive analyses.  
Sensitivity analyses include :  conducting an adjusted analysis of the primary efficacy outcome 
based on the randomized stratum and separately, based on the stratum the subject actually 
belongs, and conducting an analysis where all subjects with an Indeterminate response are considered Clinical Successes.  
22.5 Analysis of Secondar y Variables  
Analyses for the FDA secondary outcomes will be described here and in more detail in the SAP.  Analyses for the EMA secondary outcomes will be described in the SAP.  The number and percentage of subjects classified as a Clinical Success, Clinical Failure and Indeterminate by [CONTACT_3786]’s Assessment at PTE in the mITT and CE populations (by [CONTACT_494219]) will be calculated  for each 
treatment group .  A 2-sided unadjusted 95% CI will be constructed for the observed difference in 
the clinical success rate using the method of Miettinen and Nurminen .
9  For Investigator’s 
Assessment of Clinical Response at PTE in the mITT and CE populations the 2-sided 95% CI is 
for descriptive purposes only and no conclusion of NI will be made.   
The number and percentage of subjects in each treatment group in each response category for 
Early Clinical Response will be presented for the micro -mITT population.  The number and 
percentage of subjects who are classified as a Clinical Success and Clinical Failure by [CONTACT_494220] .  Two -sided unadjusted 95% 
CI will be constructed for the observed difference in the clinical success rate s using the method 
of Miettinen and Nurminen.
9 
The number and percentage of subjects with an Early Clinical Response of success and an Investigator’s Assessment of Clinical Response at PTE of Clinical Success by [CONTACT_209058] (including Gram-negative causative pathogens and MRSA) will b e provided in the micro-m ITT 
and ME populations.  
22.[ADDRESS_635843] article in the ITT population will 
be calculated.  A 2-sided unadjusted 95% CI will be constructed for the observed difference in 
the Clinical Success rate using the method of Miettinen and Nurminen.
 9  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 64 of 79 Paratek Pharma, LLC  The number and percentage of subjects classified as a Clinical Success, Clinical Failure and 
Indeterminate by [CONTACT_737]’s Assessment at EOT in the mITT and C E populations (by 
[CONTACT_494221]) will be calculated for each treatment group.  A 2-sided unadjusted 95% CI will be constructed for the 
observed difference in the clinical success rate using the method of Miettinen and Nurminen.
9 
Descriptive summaries, including change from baseline where appropriate, of the clinical signs 
and symptoms (tenderness, edema, erythema, induration and drainage), complete resolution of 
the clinical signs and symptoms, temperature, ABSSSI lesion measurements (including absolute and percentage reduction in lesion area, eg, 0 to  < 5%, 5 to  < 10%, 10 to  < 20%, ≥ 20%, etc., as 
detailed in the SAP), and systemic signs by [CONTACT_494222].   
All-cause mortality (ACM) at [ADDRESS_635844] to follow-up will be considered 
deceased for this analysis.  A 2-sided unadjusted 95% CI for the observed difference in mortality 
rates will be calculated for ACM.  
The per-subject and per-pathogen microbiologic outcomes will be provided for the micro- mITT 
and ME populations at the EOT and PTE visits.  Two-sided unadjusted 95% CIs will be provided for the differen ce in per- subject microbiological favorable outcome rates.   
A concordance analysis of Early Clinical Response and Investigator’s Assessment of Clinical Response at PTE in the mITT analysis set will also be presented.  
22.[ADDRESS_635845] results obtained during the course of the study.  For safety an alyses for both the 
FDA and EMA, subjects will be analyzed according to the treatment actually received.  
 Adverse Events  22.7.1
Summary tables will be provided for all treatment- emergent adverse events (TEAEs).  A TEAE 
is defined as an AE with a start date and time on or after the first dose of test article.  AEs will be 
coded using the Medical Dictionary for Regulatory Activities (MedDRA) and will be 
summarized by [CONTACT_494223] (SOC) and preferred term (PT).  Additional tabulations will provide summaries by [CONTACT_494224], severe TEAEs, TEAEs 
judged to be related to test article, TEAEs leading to discontinuation of test article, and TEAEs of special interest.  
 Vital Signs 22.7.2
The following variables will be analyzed descriptively:  
• Vital signs (systolic and diastolic BP, pulse rate, body temperature, resp iratory rate ), 
including change from Screening  by [CONTACT_494225] (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 65 of 79 Paratek Pharma, LLC  • Clinically no table vital signs (meeting predefined criteria  as specified in the SAP) by [CONTACT_494226] s with no table vital signs data will be  listed . 
 Electrocard iograms 22.7.3
ECG data (RR interval, PR interval, QRS interval, QT c, QTc Bazett’s Correction  Formula 
[QTcB], and QTc Fr idericia’s Correction  Formula [QTcF]) will be summarized descriptively at 
each scheduled evaluation , as noted in Section 8,  and for the overall worst post- Screening  value.  
Changes from Screening  at each visit that a 12- lead ECG is obtain ed will also be provided.  An 
outlier analysis  will be conducted based on the worst post- Screening  value.   
 Labo ratory T ests 22.7.4
The following variables will be anal yzed descriptively:  
• Laboratory variables by [CONTACT_765]  
• Change from Screening  of laboratory variables by [CONTACT_765]  
• Clinically notable laboratory values (meeting predefined criteria specified in the SAP)  by 
[CONTACT_494227].  Values meeting predefined 
criteria for being clinically no table will be flagged within the listings.  
22.8 Resource Utilization  
The fol lowing are the variables relating to resource utilization.  Data for resource utilization will 
be col lected through the Final Follow -up visit.  
• Hospi[INVESTIGATOR_494184] 
• number of emergency room visits  
Descriptive statistics for the resource utilization parameters will be provided by [CONTACT_494228] .  
22.[ADDRESS_635846]  background information.  If the actual date or time for a 
blood sample or dose is missing, the related bioanalytical determination of the PK concentration 
will be excluded from all analyses.   Om adacycline concentrations below the limit of 
quantification w ill be treated as missing data in summary statistics and for th e calculation of PK 
parameter s. 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 66 of 79 Paratek Pharma, LLC  Variables including age (year s), body weight (kg), gender, and race/ethnicity along with other 
covariates previously determined to be important will be incorporated into the population PK  
database.  Based on the subject s in the population analysis data set, descriptive summaries at 
Screening  for these variables will be reported.  Outliers may be excluded from the analysis.  
These will be determined by a scatter pl ot of the observed concentration versus time post dose 
reported.  The distribution of the number of samples contributed per subject  to the model-based 
analysis will be tabulated.  Also , simple summary descriptive statistics for the concentration of 
samples by [CONTACT_494229]. 
 Population PK  Modeling  22.9.[ADDRESS_635847] ifications (eg, fewer random a ffects or an alternative residual error model) 
may be appropriate if the diagnostics for the model suggest false convergence.  Additional covariates will be investigated graphically (gender, race/ethnicity, age) as part of the model diagnostics and some may be retained in the final model and additional ones in a competing model to deliver estimates of arguably insignificant effects.  Scatter plots of the observed 
concentrations versus population- estimated and individually estimated concentrations will be 
used as part of the overall assessment of the overall quality of the fit.  During modeling, the broad principles outlined by [CONTACT_1622]
10 will be followed.  
The individual model- based exposure measures at steady state (area under the curve [ AUC] 0-24,ss, 
time to maximum plasma concentration [T max,ss], maximum plasma concentration [ Cmax,ss]) will 
be computed and summarized. 
22.10 Pharmacogenetics/P harmacogenomics  
Pharmacogenetics/pharmacogenomics studies are not planned as part of this protocol. 
22.11 Biomarkers  
Not applicable. 
22.12 PK/PD  
The relationship between omadacycline exposure and response (efficacy and safety ) will be 
examined as appropriate for the data.  A population PK model will be used to calculate 
individu al subject AUCs and, subsequently, possible AUC/MIC breakpoints . 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635848] article in the mITT population.  An NI margin of 
10% will be used for the analysis in the mITT population.  The NI margin was based on an analysis of the historical data regarding the treatment effect of antibiotics in ABSSSI . 
In the po study of tedizolid versus linezolid, the rates of Early Clinical Response were  79% in 
both treatment arms  in the ITT population.
11  Thus, an outcome rate of 79% in the mITT 
population was used for determination of the sample size.  For the Early Clinical Response 
primary efficacy endpoint, assuming an outcome rate of 79% for both treatment groups, NI margin of 10%, 90% power and a 1-sided alpha of 0.025, using the sample size determination method of Farrington and Manning,
12 a total of 704 subjects are required.   
The rates of clinical success based on the Investigator’s A ssessment at PTE were 86% in the ITT 
population and 95% in the CE population for linezolid, in the recent po c linical study in ABSSSI 
subjects .11  To be conservative, outcome rates of 85% in the mITT and 90% in the CE population 
are used for the sample size determination.  Assuming an 85% outcome rate in both treatment 
groups, NI margi n of 10%, and a 1-sided alpha of 0.025, with a total of 704 subjects, there is 
more than 90% power to show NI for Investigator’ s Assessment of Clinical Response at PTE in 
the mITT population.  With an evaluability rate of 80%, there will be 564 subjects in  the CE 
population.  Assuming a 90% outcome rate  in both treatment groups, NI margin of 10% and a 
1-sided alpha of 0.025, 564 subjects provides more than 90% power to show NI in the CE population. 
Thus, a total of 704 subjects provide sufficient power for the primary efficacy analyses for both 
the FDA and EMA  regulatory authorities.   A summary  of the sample size calculations and 
assumptions is provided in Table  6. 
Table  6. Sample Size and Power Calculations  
 Primary Efficacy Outcome 
FDA  
(Early Clinical Response)  Primary Efficacy Outcome EMA  
(Investigator’s Assessment of Clinical Response at 
PTE) 
Population  mITT  mITT  CE 
N 704 704 564 
Outcome Rate  79% 85% 90% 
Evaluability Rate  N/A N/A 80% 
Power  90% 96% 97% 
CE = clinically evaluable ; EMA  = European Medicines Agency ; FDA  = [LOCATION_002] Food and Drug 
Administration ; mITT  = modified intent -to-treat; N = number; N/A  = not applicable ; PTE = post therapy evaluation . 
 
22.14 Interim A nalyses  
No interim an alyses of efficacy are planned . 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 68 of 79 Paratek Pharma, LLC  22.15 Handling of Missing Values/Censoring/Discontinuations  
Missing values will not be imputed  for primary and secondary efficacy and safety analyses 
(except as detailed in the SAP for missing dates) and only observed values will be used in data 
analyses and presentations.  For the primary efficacy outcome measure, if any data field needed to determine the r esponse is missing the subject will be assigned an Indeterminate response.  For 
analyses of the primary efficacy outcome, subjects with an I ndeterminate response are included 
in the denominator, and thus, are considered Clinical Failures.  A sensitivity analysis of the primary efficacy outcome will be conducted in which subjects with an I ndeterminate response 
are considered Clinical Successes.   
For the secondary outcome measure of Investigator’s Assessment of Clinical Response at PTE in 
the mITT population (co- primary for the EMA analysis), subjects with missing data are assigned 
an Indeterminate response.  Subjects with an Indeterminate response are included in the denominator, and thus, are considered failures.  Table  7 provides a summary of the handling of 
missing/indeterminate outcomes for the Investigator’s Assessment of Clinical Response at PTE.  
Table  7. Investigator’s Assessment of Clinical Response at PTE Determination 
Considering Missing Data   
EOT Visit  PTE Visit  Overall Assessment of Clinical Response at 
PTE  (Investigator’s Assessment)  
Missing /indeterminate  Success  Indeterminate  
Missing /indeterminate  Failure  Failure  
Missing /indeterminate  Missing /indeterminate  Indeterminate  
Success  Missing /indeterminate  Indeterminate  
Failure  Missing /indeterminate  Failure  
EOT  = end of treatment ; mITT = modified intent -to-treat population ; PTE = post therapy evaluation.  
For the analysis in the mITT analysis set of Investigator’s Assessment of Clinical Response at PTE, indeterminate responses  are included in the denominator and are thus  considered clinical failures.  
Missing data are handled in a similar  manner for the outcome of mic robiological response at PTE.   
 SUBJECT IDENTIFICATI ON [ADDRESS_635849] keep that number throughout the study even if he/she transfers to another site.  A subject who discontinues 
participation or is withdrawn before receiving a treatment assignment code, and who re- enrolls at 
a later time will be assigned a new subject number and recorded as rescreened .  The investigator 
must maintain a subject master log  of all subjec ts.  
 TEST ARTICLE ACCOUNT ABILITY, RECONCILIATION, AND [ADDRESS_635850] that has 
been supplied by [CONTACT_456].   
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635851] article return/destruction must be documented.   
24.[ADDRESS_635852] 
article s, packaging, drug labels, and send a copy of the completed medication accountability 
ledger to the monitor or to the address provided to the investigator. 
 RANDOMIZATION AND BLINDING  25
25.1 Treatment Assignment  
All eligible subjects will be randomized via an IxRS that assigns them to 1 of the treatment arms (in a 1:1 ratio).  The site delegate will contact [CONTACT_47893] (via phone or web) after confirming that the subject fulfills all the inclusion criteria and none of the exclusion criteria.  The IxRS will assign a test article to the subject based on a computer-generated randomization schedule.  The randomization will be a blocked randomization sequence stratified by [CONTACT_180890] (wound infection, cellulitis /erysipelas or major abscess)  and receipt of an al lowed antibacterial therapy 
(see Appendix 1) in the [ADDRESS_635853] actually receives any medication .  Enrollment of 
subjects with major abscess will be capped at 30% of the subjects randomized.   Enrollment of 
subjects who have received an allowed antibacterial therapy in the 72 hours prior to randomization will be capped at 25% of the subjects randomized.   
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635854] arti cle kit  to be administered. The study 
coordinator/staff will instruct the subject on the use of po test article.   
25.3 Treatment B linding  
The investigator and sponsor will be blinded to treatment arm assignments throughout the study.  
The sponsor designee (eg, study statistical team, IxRS vendor, etc.) will have a designated 
randomization administrator who will maintain the randomization codes in accordance with standard operating procedures to ensure the blind is properly maintained, and that only sponsor personnel who require knowledge of treatment assignments will be unblinded (eg, staff involved in maintaining the randomization codes or SAE reporting).  
The study will follow a double-dummy design.  Subjects assigned to omadacycline will r eceive 
active omadacycline tablets and over- encapsulated linezolid placebo tablets.  Subjects assigned 
to the linezolid arm will receive omadacycline placebo tablets and over -encapsulated active 
linezolid tablets.  
Randomization data are kept strictly confidential until the time of database lock and unblinding 
at the end of the study.  
All eCRFs must be completed, entered and checked; all safety laboratory results must have been 
reported; all AEs must have been fully characterized (eg, relationship to test article determined) 
and coded; and all queries must have been resolved prior to database lock and unblinding.  Determination of inclusion in the analysis populations, characterization of protocol deviations as major/minor and final approval of the SAP will also be completed prior to database lock.  
Plasma samples for subjects receiving omadacycline may be analyzed during the course of the study.  To permit the sponsor to review the drug concentration data prior to locking the dataset 
and without unblinding, any PK data provided prior to unblinding will be re- coded by [CONTACT_494230]. 
Unblinding is only to occur in the case of subject emergenci es (see Section  25.4) and at the 
conclusion of the study. 
25.[ADDRESS_635855]  the 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 71 of 79 Paratek Pharma, LLC  sponsor or sponsor’s designated Medical Monitor or designee to confirm the need to unblind, 
prior to unblinding.  However, if required , the investigator can unblind without consulting the 
Medical Monitor.  
Emergency code breaks are performed using the IxRS.  When the investigator contacts the 
system to unblind a subject, he/she must provide the requested subject identifying information and confirm the necessity to unblind the subject.  The investigator will then receive details of the 
drug treatment for the specified subject and a fax or e- mail confirming th at the treatment 
assignment of the subject was unblinded.  The system will automatically inform the sponsor’s 
monitor for the site and the sponsor that the code has been broken. 
It is the investigator ’s responsibility to ensure that there is a procedure in place to allow access to 
the IxRS code break information in case of emergency.  The investigator will inform the subject 
how to contact [CONTACT_5657]/her backup in cases of emergency when he/she is unavailable.  The 
investigator will provide protocol number, test article name [CONTACT_90228], subject number, and instructions for contact[CONTACT_20610] (or any entity to which it has delegated responsibility for emergency code breaks) to the subject in case emergency unblinding is required at a time when the investigator and backup are unavailable. 
In the event of a medical emergency in which the investigator judges that the subject cannot be 
managed safely without unblinding, the investigator may obtain the treatment allocation directly from the research pharmacist.   All steps outlined above will be followed, including contact[CONTACT_494231] [ADDRESS_635856]’s premature withdrawal from the study and record this information on the eCRF. 
Subjects who discontinue study treatment (unless that subject withdraws informed consent) 
should NOT be considered withdrawn from the study.  The date and primary reason for discontinuation of study treatment should be recorded in source documents.  Subjects who discontinue the study treatment should have the EOT visit and the procedu res listed for that visit 
in Section  8, a PTE visit and a Final Follow -up Assessment, if possible.  The site shoul d also 
collect subject safety information through the Final Follow -up assessment.   
Site personnel should also contact [CONTACT_138858]’s discontinuation from test article.   
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635857] to follow-up, the investigator should show "due diligence" by 
[CONTACT_762], eg, dates of telephone calls, registered letters, etc.  
Subjects who are prematurely withdrawn from the study will not be replaced by [CONTACT_494232].  
 STUDY SUSPENSION, TE RMINATION, AND COMPLETION  [ADDRESS_635858] been made.  Visits include the final 
follow- up visit (Final Follow -up).  The study will be completed when the last subject has either 
discontinued or completed the Final Follow-up visit.   
No long- term follow -up of subjects is planned, with the exception of pregnancies, as described in 
Section 21.2.6, and SAEs described in Section 21.2. Sites will be notified by [CONTACT_494233].  Subjects already consented will be allowed to continue in 
the study. Upon study completion, the i nvestigator will provide the sponsor, IRB/IEC /REB, and regulatory 
agency with final reports and summaries as requ ired by [CONTACT_19124].  The investigator must 
submit a written report to the sponsor and the IRB/IEC /REB within [ADDRESS_635859]’s interests.  The investigator will be responsible for informing 
Institutional Review Boards (IRBs) and/or Ethics Committees (ECs) of the early termination of the study. 
If the investigator suspends or terminates the study, the i nvestigator will promptly in form the 
sponsor and the IRB/IEC /REB and provide them with a detailed written explanation.  Subjects 
should be seen as soon as possible and treated as described in Section [ADDRESS_635860] article s, containers, and other study 
materials to the sponsor. 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 73 of 79 Paratek Pharma, LLC   ETHICAL CONSIDERATIONS 28
28.1 Regulatory and Ethical C ompliance  
This clinical study was designed and shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guideline for Good Clinical Practice  (GCP) , with applicable local 
regulations (including European Directive 2001/20/EC, United  States [ US] Code of Federal 
Regulations [CFR]  Title 21, and Japanese Ministry of Health, Labor, and Welfare), and with the 
ethical principles laid down in the Declaration of Helsinki.  
28.[ADDRESS_635861] be 
reviewed by [CONTACT_138849]/IEC /REB. 
Before any procedures specified in the protocol are performed, a subject must: 
• Be informed of all pertinent aspects of the study and all elements of informed consent  
• Be given time to ask questions and time to consi der the decision to participate  
• Voluntarily agree to  participate in  the study 
• Sign and date an IRB/IEC /REB approved ICF  
28.3 Responsibilities o f the Investigator  and IRB/IEC/REB  
The protocol and the proposed ICF  must be reviewed and approved by a properly constituted 
IRB/IEC /REB before study start.  A signed and dated statement that the protocol and ICF have 
been approved by [CONTACT_1201]/IEC /REB must be given to the sponsor before study initiation.  Prior 
to study start, the investigator is required to sign a protocol signature [CONTACT_5389]/her 
agreement to con duct the study in accordance with these documents and all of the instructions 
and procedures found in this protocol, and to give access to all relevant data and records to the 
sponsor monitors, auditors, designated agents of the sponsor, IRBs/IECs/REBs, and regulatory authorities as required.  If an inspection of the clinical site is requested by a regulatory authority, the investigator must inform the sponsor immediately that this request has been made.  
 PROTOCOL ADHERENCE  [ADDRESS_635862] be considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_138849]/IEC /REB, it cannot be implemented.  All significant protocol deviations will be recorded 
and reported in the clinical study report (CSR). 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635863] be approved by [CONTACT_456] , Health Authorities where req uired, and the IRB/IEC /REB .  
Only amendments that are required for subject safety may be implemented prior to 
IRB/IEC /REB approval.  Notwithstanding the need for approval of formal protocol amendments, 
the investigator is expected to take any immediate act ion required for the safety of any subject 
included in this study, even if this action represents a deviation from the protocol.  In such cases, the sponsor should be notified of this action and the IRB/IEC /REB  at the study site should be 
informed within 10 working days. 
 QUALITY CONTROL AND ASSURANCE  30
The sponsor performs quality control and assurance checks on all clinical studies that it sponsors.  
Before enrolling any subjects in this study, sponsor personnel and the i nvestigator  review the 
protocol, the Investigator’s Brochure , the case report forms  (CRFs ) and instructions for their 
completion, the procedure for obtaining informed consent, and the procedure for reporting AEs and SAEs.  A qualified representative of the sponsor monitors the conduct of the study by 
[CONTACT_138861] e- mail.  During these site visits, 
information recorded in the CRFs is verif ied against source documents.  
 DIRECT ACCESS, DATA HANDLING, AND RECORD -KEEPI[INVESTIGATOR_1645]  31
31.1 Investigator  
The investigator will permit study -related monitoring, audits, IRB/IEC /REB review, and 
regulatory inspections by [CONTACT_60282]. 
All information will be recorded on source documents.  All required data will be recorded in the 
eCRFs.  
If an investigator retires, relocates, or otherwise withdraws from conducting the study, the 
investigator must notify the sponsor to agree upon an accep table storage solution.  Regulatory 
agencies will be notified with the appropriate documentation. 
An updated form 1572 will be filed with the sponsor for any changes in the study personnel 
reported in the current form 1572. 
31.2 Sponsor  
The data is entered into an electronic database via eCRFs .  The Sponsor M edical Monitor 
reviews the data for safety information.  The data is reviewed for completeness and logical 
consistency.  Automated validation check s identify missing data, out-of-range data, and other 
data inconsistencies.  The central safety and microbiology data will be processed electronically.  
Requests for data clarification are forwarded to the investigative site for resolution.  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.[ADDRESS_635864] to specific provisions in the clinical study agreement (CSA), if a subject is 
injured as a direct result of a test article, the sponsor will pay f or reasonable and necessary 
medical treatment for the injury, to the extent that such expenses are not covered by [CONTACT_423]’s medical insurance, a government program, or other responsible third party.  If laws or regulations of the locality in which the study is taking place require additional payment of expenses, the sponsor shall comply with such laws or regulations.  Where applicable, the sponsor 
has taken specific national insurance.  
 PRESTUDY DOCUMENTATI ON [ADDRESS_635865] provide the sponsor with the following documents BEFORE enrolling any 
subjects:  
• Completed and signed form 1572 
• All applicable co untry-specific regulatory forms 
• Current signed and dated curricula vitae for the investigator, sub-investigators, and other 
individuals having significant investigator responsibility who are listed on the form 1572 or 
equivalent, or the clinical study information form 
• Copy of the IRB/IEC /REB approval letter for the protocol and informed consent.  All 
advertising, recruitment, and other written information provided to the subject must be 
approved by [CONTACT_1201]/IEC /REB.  Written assurance of continuing approval (at least annually) 
as well as a copy of the annual progress report submitted to the IRB/IEC /REB  must also be 
provided to the sponsor.   
• Copy of the IRB/IEC /REB-approved informed consent document to be us ed 
• Where applicable, a list of the IRB/IEC /REB members and their qualifications, and a 
description of th e committee’s working procedure 
• Copy of the protoc ol sign -off page signed by [CONTACT_093] 
• Fully executed CSA 
• Where applicable, a financial discl osure form 
• A written document containing the name, location, certification number, and date of 
certification of the laboratories  to be used for laboratory assays and those of other facilities 
conducting tests.  This document should be returned along with the statement of investigator 
form.  The sponsor must be notified if the laboratory is changed or if any additional laboratory is to be used.  
• List of normal laboratory values and units of measure for all laboratory tests required by [CONTACT_12695].  This is required for each laboratory to be used during the study.  The sponsor must 
be notified if normal values or units of measurement change. 
 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 76 of 79 Paratek Pharma, LLC   RECO RDS RETENTION 34
The investigator shall retain and preserve 1 copy of all data generated in the course of the study, 
specifically including but not limited to those defined by [CONTACT_138875], for the longer of :  (a) 
[ADDRESS_635866] article  or (b) 
such longer period as required by [CONTACT_319352].  At the end of such 
period, the investigator shall notify the sponsor in writing of its intent to destroy all such material.  The sponsor shall have 3 0 days to respond to the i nvestigator ’s notice, and the sponsor 
shall have a further opportunity to retain such materials at the sponsor ’s expense.  
 PUBLICATION POLICY 35
The sponsor assures that the key design elements of this protocol will be posted in a publicly 
accessible database such as clinicaltrials.gov .  In addition, upon study completion and 
finalization of the study re port, the results of this study will be either submitted for publication 
and/or posted in a publicly accessible database of clinical study  results.  
Upon completion of the study, the i nvestigator  may publish the results in recognized (refereed) 
scientific journals subject to the provisions of the CSA.  Unless otherwise specified in the CSA, the following process shall occur: 
The institution and Principal Investigator (PI) shall not publish or pres ent data from an individual 
study center until the complete multi -center study has been presented in full or for [ADDRESS_635867] 
refer to the multi- center  findings.  Thereafter, if the PI  [INVESTIGATOR_494185], the institution and PI [INVESTIGATOR_494186], abstracts, manuscripts, 
and/or other presentation materials to the sponsor for review before submission for publication or 
presentation.  The sponsor shall have [ADDRESS_635868] a patent application(s) filed. 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 77 of 79 Paratek Pharma, LLC   REFERENCES (A VAILABLE UPON RE QUEST)  36
 
1. David MZ, Daum RS . 2010. Community- Acquired Methi cillin -Resistant Staphylococcus 
aureus:  Epi[INVESTIGATOR_494187]. Clin. 
Microbiol. Rev. 23(3):616 -87. 
2. Paratek Pharmaceuticals, Inc. 2016 Omadacycline/PTK 0796 Investigator's Brochure, Edition 9.0. 
3. FDA. 2013. Guidance for Industry:  Acute Bacterial Skin and Skin Structure Infections:  Developi[INVESTIGATOR_76508]. CDER. 
4. EMA. 2011. Gui deline on the evaluation of medical products indicated for treatment of 
bacterial infections. European Medicines Agency. CPMP/EWP/558/95  rev 2. 
5. EMA. 2013. Addendum to the guideline on the evaluation of medicinal products indicated 
for treatment of bacte rial infections (CPMP/EWP/558/9 5 Rev 2), European Medicines 
Agency. EMA/CHMP/351889/2013.] 
6. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL, 
Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. 2014. Practice Guidelines for the Diagn osis and Management of Skin and Soft Tissue Infections:  [ADDRESS_635869]. Dis. 59 :10-52. 
7. Talbot GH, Powers JH, Fleming TR, Siuciak JA, Bradley J, Boucher H on behalf of the 
CABP -ABSSSI Project Team . 2012. Progress on Developi[INVESTIGATOR_494188] -Acquired Bacterial Pneumonia and Acute Bacterial Skin and 
Skin Structure Infections :  Update From the Biomarkers Consortium of the Foundation for 
the National Institut es of Health. Clin. Infect. Dis. 55:1114- 21. 
8. McCaffery, M, Beebe, A. 1993. Pain: Clinical Manual for Nursing Practice. Baltimore: V.V. 
Mosby [CONTACT_25264]. 
9. Miettinen O, Nurminen M. 1985. Comparative Analysis of T wo Rates. Statistics in Medicine 
4:213-26. 
10. FDA. 1999. Guidance for Industry, Population Pharmacokinetics. Center for Drug Evaluation 
and Research, U.S. Department of Health and Human Services February 1999. 
11. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. 2013. Tedizolid Phosphate vs Linezolid 
for Treatment of Acute Bacterial Skin and Skin Structure Infections: The ESTABLISH -
1 Randomized Trial. JAMA. 309:559-69. 
12. Farrington CP, Manning G. 1990. Test Statistics and Sample Size Formulae for Comparative 
Binomial Trials with Null Hypothesis of Non-zero Risk Difference or Non -unity Relative 
Risk Statistics in Medicine 9 :1447- 54. 
 
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 78 of 79 Paratek Pharma, LLC  Appendix 1.  Allowed and Disallowed Prior Antibiotics  
Allowed Antibiotics  
(One d ose within  72 hours prior to randomization *) Disallowed Antibiotics  
Penicillins  
Amoxicillin  Nafcillin  Benzathine/Penicillin -G Procaine  
Amoxicillin -Clavulanate  Oxacillin   
Amoxicillin -Sulbactam  Penicillin -G or -V  
Ampi[INVESTIGATOR_213655] -Sulbactam  Pi[INVESTIGATOR_049] -Tazobactam   
Dicloxacillin  Ticarcillin -Clavulanate   
Cephalosporins  
Cefaclor  Cefpodoxime  Cefixime (40 0 mg) 
Cefadroxil  Cefprozil  Ceftriaxone  
Cefazolin  Ceftaroline  
Cefdinir  Ceftazidime  
Cefepi[INVESTIGATOR_213656] (20 0 mg) Cefuroxime  
Cefditoren  Cephalexin  
Cefotaxime  Loracarbef  
Carbapenems  
Doripenem  
Imipenem  
Meropenem  Ertapenem  
Glycopeptides  
Televancin  Dalbavancin  
Vancomycin  Oritavancin  
Fluoroquinolones  
Ciprofloxacin  Levofloxacin  
Moxifloxacin  
Macrolides  
Clarithromycin  
Erythromycin  Azithromycin  
Clarithromycin XL  
Tetracyclines  
Doxycycline (10 0 mg) 
Minocycline  Doxycycline (20 0 mg) 
Minocycline Extended Release 
Tigecycline  
Oxazolidinones  
 Linezolid  
Tedizolid  
Miscellaneous  
Clindamycin  
Metronidazole  
Trimethoprim -sulfamethoxazole/Co -trimoxazole   
*Prior (within 7 2 hours prior to randomization ) administration of potentially effective  systemic antibacterial th erapy 
is an exclusion criterion ; however, subjects may be eligible for the study despi[INVESTIGATOR_494189] a single dose of a short -actin g systemic antibiotic within [ADDRESS_635870] eligibility.  
Omadacycline (PTK 0796)   
PTK0796 -ABSI -[ZIP_CODE] – Version 3.0  IND 73,431 
22-NOV -2016  IND 75,928 
 
Confidential and Proprietary  Page 79 of 79 Paratek Pharma, LLC  Appendix 2.  Equations and Conversion Factors  
1. Cockcroft- Gault equation to calculate creatinine clearance ( CrCL) (relevant to Exclusion 
Criterion number 8): 
 
(140-age[yrs])  * weight [kg]  * (Z)  Z = 1.0, if Male  
Z = 0.85, if Female  Cr [mg/dL] * 72 
 
2. mm3 = µL  
 
3. cc = mL  
 
4. Conversion of  immature neutrophils (band) forms in  K/µL or K/mL to % bands (relevant to 
Inclusion Criterion number 4 and Exclusion Criterion number 11):  
[(bands K/ µL)/(total WBC  K/µL)] × 100 = % bands 
Or 
[(bands K/ mL)/(total WBC  K/mL )] × 100 = % bands 
  